

## **CURRICULUM VITAE**

**ALIK FARBER M.D., M.B.A., F.A.C.S.**

### **PERSONAL INFORMATION**

Office Address: 1 Boston Medical Center Place  
Collamore 5, Suite D-506  
Boston Medical Center  
Boston, MA 02118

Office Telephone: (617) 414-7709

Personal Telephone: (310) 968-6083

Email: [af1066@gmail.com](mailto:af1066@gmail.com)

### **EDUCATION**

1987 B.S. (Biology) Brown University, Providence, RI

1992 M.D. Harvard Medical School, Boston, MA

2019 M.B.A. Heller School for Social Policy and Management  
Brandeis University, Boston, MA

### **POST GRADUATE TRAINING**

1992 - 1993 Internship in General Surgery, Massachusetts General Hospital;  
Boston, MA

1993 - 1997 Residency in General Surgery, Massachusetts General Hospital;  
Boston, MA

1997 - 1999 Fellowship in Vascular Surgery, Dartmouth-Hitchcock Medical  
Center; Lebanon, NH

7 - 11/1999 Fellowship in Endovascular Surgery, Southern Illinois University  
School of Medicine; Springfield, IL

### **EXECUTIVE CONTINUING EDUCATION**

11/2016 Leadership Development for Physicians in Academic Health  
Centers

Harvard T.H. Chan School of Public Health

6/2017

Leadership Program in Health Policy and Management  
Brandeis University Heller School for Social Policy and Management

## **LICENSURE**

|               |                 |
|---------------|-----------------|
| Massachusetts | 153167 (active) |
| California    | G85484          |
| Illinois      | 36100659        |
| New Hampshire | 1011            |

## **CERTIFICATION**

American Board of Vascular Surgery (Certificate No. 101103)  
American Board of Surgery (Certificate No. 43641)  
Registered Vascular Technologist (Certificate No. 80875)

## **ACADEMIC APPOINTMENTS**

|             |  |
|-------------|--|
| 2005 - 2007 | Assistant Professor<br>Department of Surgery<br>Boston University School of Medicine<br>Boston, MA     |
| 2007 - 2015 | Associate Professor<br>Department of Surgery<br>Boston University School of Medicine<br>Boston, MA     |
| 2009 - 2015 | Associate Professor<br>Department of Radiology<br>Boston University School of Medicine<br>Boston, MA   |
| 2015 -      | Professor<br>Department of Surgery and Radiology<br>Boston University School of Medicine<br>Boston, MA |

## **PROFESSIONAL APPOINTMENTS**

|             |  |
|-------------|--|
| 1999 - 2005 | Attending Vascular Surgeon<br>Cedars-Sinai Medical Center, Los Angeles, CA<br>Midway Medical Center, Los Angeles, CA<br>Century City Medical Center, Los Angeles, CA |
|-------------|--|

|                            |  |
|----------------------------|--|
|                            | Brotman Medical Center, Culver City, CA<br>St. John's Health Center, Santa Monica, CA                  |
| 2002 - 2005                | Vice-Chair<br>Department of Surgery<br>Midway Medical Center, Los Angeles, CA                          |
| 2004 - 2005                | Clinical Chief<br>Division of Vascular Surgery<br>Cedars-Sinai Medical Center, Los Angeles, CA         |
| 2005 -                     | Attending Vascular Surgeon<br>Boston Medical Center  |
| 2005 - 2009                | Director of Vascular Research<br>Boston Medical Center   |
| 2005 -                     | Co-Director of Vascular Noninvasive Laboratory<br>Boston Medical Center                                |
| 2005 - 2009                | Co-Director of Endovascular Surgery<br>Boston Medical Center   |
| 2006 - 2008                | Clinical Director<br>Section of Vascular Surgery<br>Boston Medical Center, Boston, MA                  |
| 2008 -                     | Chief<br>Division of Vascular and Endovascular Surgery<br>Boston Medical Center, Boston, MA            |
| 2010 - 2012<br>2016 - 2018 | Program Director<br>Vascular Surgery Fellowship<br>Boston Medical Center, Boston, MA                   |
| 2011 - 2018                | Medical Director,<br>Catheterization and Angiography Laboratories<br>Boston Medical Center, Boston, MA |
| 2014 -                     | Associate Chair for Clinical Operations<br>Department of Surgery<br>Boston Medical Center, Boston, MA  |

## **ACADEMIC AWARDS AND DISTINCTIONS**

Phi-Kappa-Psi Ben King Scholarship, Brown University, 1985

Sigma Xi National Science Honor Society, Brown University, 1987

Magna cum laude, Brown University, 1987

Paul Dudley White Traveling Fellowship, Harvard Medical School, 1989

Howard Hughes Medical Institute - National Institutes of Health Research Fellowship,  
National Cancer Institute, 1990-91

Honors Thesis: *The biologic behavior of a non-immunogenic murine tumor modified by the  
insertion of the gene for TNF $\alpha$* , Harvard Medical School, 1992

Cum laude, Harvard Medical School, 1992

Golden Apple Award for Excellence in Teaching, Cedars-Sinai Medical Center, 2003

Boston Magazine's "Top Doctor Award", 2010 - 2018

New England Society for Vascular Surgery Clinical Trials Grant, 2012

Society for Vascular Surgery Distinguished Fellowship, 2013

National Heart, Lung, and Blood Institute U01 Grant, 2013

Society for Vascular Surgery Foundation Multicenter Clinical Studies Planning Grant, 2014

Wallace H. Coulter Foundation Award, 2016

Presidential Guest Lecturer, Western Society for Vascular Surgery Annual Meeting, 2016

American College of Surgeons/New England Surgical Society Health Policy Scholarship, 2017

Faculty Inductee, Alpha Omega Alpha, 2018

## **PROFESSIONAL SOCIETIES**

Society for Vascular Surgery

2009 - 2016 International Relations Committee

2009 - 2012 Liaison, Vascular Resident Section

2016 - Research Council

2016 - Program Committee

2016 - *ad hoc* Committee on Industry-sponsored Clinical Trials

2018 - Document Oversight Committee

2019 - Paclitaxel Safety Task Force

Western Vascular Society  
 Southern California Vascular Surgical Society  
 International Society for Endovascular Therapy  
 International Society for Vascular Surgery  
     2013 - 2016      **Secretary**  
 Society for Clinical Vascular Surgery  
     2016 -              Program Committee  
     2018 - 2019      **-Chair**  
 International College of Angiology  
 American Russian Medical Association  
     2003 - 2005      **Treasurer**  
 Massachusetts Medical Society  
 Frederick A. Collier Surgical Society  
 Massachusetts General Hospital Surgical Society  
 New England Surgical Society  
 New England Society for Vascular Surgery  
     2015 - 2019      Program Committee  
     2018 - 2019      **-Chair**  
     2019 -              Allied Health Committee  
     2019 -              **-Chair**  
 Association for Academic Surgery  
 American College of Surgeons  
     2010 -              Fellow  
     2016-              **Councilor, Massachusetts Chapter**  
     2019 -              Massachusetts Chapter Program Committee  
 Society of University Surgeons  
     2013 - 15          Publication Committee  
     2017 - 2019      Ethics and Conflict of Interest Committee  
 Surgical Biology Club II  
 American Surgical Association

## COMMITTEE AND ADMINISTRATIVE ACTIVITIES

### Institutional

St. John's Health Center, Santa Monica, CA  
     2000 - 2001      Cardiovascular Quality Improvement Committee  
 Midway Medical Center, Los Angeles, CA  
     2002 - 2005      Medical Executive Committee  
     2004 - 2005      Wellbeing Committee  
 Boston Medical Center, Boston MA  
     2005 -              Residency Advisory Committee  
     2006 -              Operating room/Perioperative Services Committee  
     2006 - 2014      Endovascular Operations Committee  
     2008 - 2014      **- Chair**  
     2007 - 2008      Ophthalmology Chairperson Search Committee

|             |  |
|-------------|--|
| 2008 -      | Medical Executive Committee  |
| 2010 - 2013 | Supply Chain Steering Committee                                    |
| 2014 -      | Inpatient Clinical Operations Committee                            |
| 2014 -      | Procedural Clinical Operations Executive Committee                 |
| 2014 - 2017 | Utilization Management Committee                                   |
| 2015 -      | Operating Room Executive Committee                                 |
| 2016 - 2019 | - <b>Surgery Site Officer</b>                                      |
| 2015 - 2016 | Radiology Chairperson Search Committee                             |
| 2016 -      | Value Analysis Steering Committee                                  |
| 2018 -      | - <b>Chair</b>   |
| 2017 -      | Department of Surgery Promotions Committee                         |
|             | - <b>Chair</b>   |
| 2018 - 2019 | Whitaker Cardiovascular Institute Director Search Committee        |
| 2018 - 2019 | Nephrology Chief Search Committee                                  |
| 2018 -      | Endovascular Executive Committee                                   |
| 2018 -      | Interventional Procedural Platform (IPP) Steering Committee        |
| 2018 -      | Inpatient Accountable Care Organization Operations Oversight Group |

## Regional

|             |   |
|-------------|---|
| 2004 - 2006 | Expert Medical Reviewer, Medical Board of California  |
| 2007 - 2010 | Data and Safety Monitoring Board (DSMB)<br>iCast Iliac Stent Pivotal Study (Atrium Medical)           |
|             | - <b>Chair</b>  |
| 2010 - 2013 | Boston Medical Center Delegate, CIMIT<br>(Center for Integration of Medicine & Innovative Technology) |
| 2008 - 2011 | Data and Safety Monitoring Board (DSMB)<br>SAPPHIRE WW Carotid Stenting Trial (Cordis)                |
|             | - <b>Chair</b>  |
| 2011 - 2015 | Quality Committee, Vascular Study Group of New England  |
|             | - <b>Chair</b>  |

## GRANT SUPPORT

### Current

1. U01HL107352-01A1 10/01/2013 -  
NIH / NHLBI  
***Best Endovascular versus Surgical Therapy in patients with Critical Limb Ischemia (BEST-CLI) Trial***  
This is an international, multicenter, multispecialty, pragmatic, prospective, randomized, controlled, open-label, superiority trial that will compare treatment efficacy, functional outcomes and cost of infrainguinal bypass and endovascular therapy in patients with critical limb ischemia and infrainguinal atherosclerosis. This trial aims to enroll 2,100 patients at 160 sites in North America, Europe and New Zealand. Trial leadership comprises a closely integrated group of investigators based at a Clinical Coordinating Center (Brigham and Women's Hospital, Boston Medical Center and Massachusetts General Hospital, Boston,

MA), and Data Coordinating Center (New England Research Institute, Inc. Watertown, MA).

**Role: Trial Co-Chair/National Principal Investigator**

Secondary leadership positions: Chair, Site Selection and Management Committee  
Chair, Recruitment and Retention Committee  
Chair, Publications and Presentations Committee

Direct costs (trial): \$27,0000,000

Direct costs (individual): \$1,351,166

2. NCT02492854 06/01/2015 -  
Smith and Nephew  
*Standard versus negative pressure vacuum dressings (PICO) in lower-extremity bypass patients (PICO-LEB)*  
Role: Co-Investigator  
Direct Costs: \$45,000
3. NCT 02381509 08/01/2016 -  
Inferior Vena Cava Filter Study Group Foundation  
*Predicting the safety and effectiveness of Inferior Vena Cava Filters (PRESERVE) trial.*  
Role: Co-Investigator  
Direct Costs: \$34,200
4. Wallace H. Coulter Foundation 08/01/2016 -  
Grant awarded to fund *ex vivo* and *in vivo* testing of a multiple dose balloon catheter for the treatment of peripheral artery disease  
Role: Co-Investigator  
Direct Costs: \$100,000
5. NCT03242343 01/08/2018 -  
Laminate Inc.  
*Multicenter prospective study to evaluate the safety and effectiveness of the VasQ external support for arteriovenous fistula.*  
Role: Principal Investigator  
Direct Costs: \$130,350
6. Patient Safety Grant 10/1/2018  
Boston Medical Center Insurance Company  
*High Performance OR Teams Pilot with Planned Future Adoption of High Performance Team Construct Across the Boston Medical Center Operating Room*  
Role: Co-Principal Investigator  
Direct Costs: \$12,000
7. Innovation Grant 8/13/2019  
HealthTrust  
*High Performance OR Teams at Boston Medical Center*

Role: Project Lead  
Direct Costs: \$50,000

## GRANT SUPPORT

### Completed

1. Corgentech, Inc. 09/1/2002 – 07/02/2004  
*PREVENT III: Phase III, prospective, multicenter, double blind, randomized, placebo controlled trial of CGT003 (E2F Decoy) in the prevention of lower extremity vein bypass failure.*  
Role: Co-Investigator  
Direct Costs: \$150,000
2. Intercytex, Ltd 08/06/2005 – 09/01/2008  
*TOPICAL II: Phase III, prospective, multicenter, double blind, randomized, placebo controlled trial to evaluate the safety and efficacy of ICXP007 (allogeneic wound care stimulant product) with four layer therapeutic compression for treatment of venous stasis ulcers).*  
Role: Principal Investigator  
Direct Costs: \$ 190,882.68
3. Angen, Inc 11/20/2006 – 06/01/2008  
*Phase II double blind, randomized, placebo-controlled study to assess the safety and efficacy of AMG001 (hepatocyte growth factor plasmid) to improve perfusion in patients with critical limb ischemia*  
Role: Principal Investigator  
Direct Costs: \$ 24,424.82
4. Covidien, Inc 04/04/2007 – 06/05/2008  
*Confluent Pivotal Trial - Phase II trial to assess safety and efficacy of a Vascular Sealant System compared to gelfoam and thrombin for control of anastomotic suture-line bleeding in patients undergoing vascular surgery with PTFE grafts*  
Role: Principal Investigator  
Direct Costs: \$ 7,787.09
5. Genzyme, Inc 10/17/2007 – 10/01/2010  
*WALK Study: Phase II trial to assess the safety and efficacy of Ad2/HIF-1 $\alpha$ /VP16 (adenoviral vector) to treat severe intermittent claudication*  
Role: Principal Investigator  
Direct costs: \$ 6,800.00
6. CVRX, Inc 06/07/2007 – 12/05/2008  
*Phase II trial to assess safety and efficacy of an implantable medical device that electrically activates the baroreflex reflex in the treatment of refractory hypertension.*  
Role: Principal Investigator  
Direct Costs: \$ 6,889.00



7. R21DK084390-01 07/01/2009 – 06/30/2012  
 NIH/NHLBI  
*The Role of Nitric Oxide in Arteriovenous Fistula Maturation*  
 In this study the role of SERCA and Nitric Oxide was evaluated in smooth muscle cells cultured from cephalic veins of patients undergoing arteriovenous fistula creation.  
 Role: Co-Investigator
  
8. Talecris Biotherapeutics, Inc. 10/01/2011 –02/29/2012  
*Phase 2, Randomized, open label study to evaluate the effects of different intrathrombus infusion regimens of plasmin compared to plasminogen activator and placebo in patients with acute lower extremity native artery or bypass graft occlusion*  
 Role: Principal Investigator  
 Direct Costs: \$ 25,000
  
9. Healthpoint Ltd 8/21/2009 - 12/01/2011  
*Phase II, randomized, double-blind, placebo controlled, dose finding study investigating the efficacy of HP802-247 in venous leg ulcers.*  
 Role: Principal Investigator  
 Direct Costs: \$ 90,350.00
  
10. Grifols 06/07/2012 - 07/01/2015  
*Prospective, single-blind, randomized, Phase III study to evaluate the safety and efficacy of a fibrin sealant as an adjunct to hemostasis during peripheral vascular surgery.*  
 Role: Co - Investigator  
 Direct Costs: \$99,848
  
11. Aastrom 07/13/2012 - 05/01/2013  
*Multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of Ixmyelocel-T in subjects with critical limb ischemia and no options for revascularization*  
 Role: Co- Investigator  
 Direct Costs: \$34,956
  
12. Celleration 07/07/2012 - 05/11/2014  
*IN-BALANCE VLU (Inflammation, Bacteria, & Angiogenesis effects in Launching Venous Leg Ulcer healing; A Clinical Evaluation)*  
 Role: Principal Investigator  
 Direct Costs: \$90,900
  
13. Smith and Nephew (Healthpoint) 09/01/2012 - 09/01/2015  
*Phase 3 Randomized, double-blind, vehicle controlled study investigating the safety and efficacy of HP802-247 in the treatment of venous leg ulcers*  
 Role: Principal Investigator  
 Direct Costs: \$304,000

14. Smith and Nephew (Healthpoint) 09/01/2012 - 08/01/2015  
*Phase 3, randomized, double-blind, vehicle controlled study investigating the safety and efficacy of HP802-247 in the treatment of venous leg ulcers ( $>12\text{ cm}^2$  to  $\leq 36\text{ cm}^2$ )*  
 Role: Principal Investigator  
 Direct Costs: \$125,004
  
15. Smith and Nephew (Healthpoint) 05/01/2013 - 10/30/2015  
*Non-interventional, safety study providing 12 month follow-up from first exposure to HP802-247 in subjects with venous leg ulcers*  
 Role: Principal Investigator  
 Direct Costs: \$43,480
  
16. Grifols (GTI1304) 01/31/2013 - 12/31/2015  
*Observational study of Tissue Plasminogen Activator used for catheter- directed thrombolysis in patients with acute lower extremity native artery or bypass graft occlusion*  
 Role: Principal Investigator  
 Direct Costs: \$76,602
  
17. Macrocare (NCT02130310) 10/09/2014 - 11/30/2015  
*Phase-3, prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and efficacy of CureXcell® as an adjunct to good ulcer care measures in treating chronic venous leg ulcers*  
 Role: Principal Investigator  
 Direct Costs: \$47,589
  
18. Society for Vascular Surgery Foundation Multicenter Clinical Studies Planning Grant  
*The Vascular Physician Offer and Report (VAPOR) Trial* 07/01/2014 - 06/30/2015  
 This was a national pilot, cluster-randomized trial of a smoking cessation protocol developed by the Quality Committee of the Vascular Study Group of New England. The Offer and Report Protocol consists of three elements: 1) standardized, scripted, in-person “very brief advice” regarding smoking cessation, 2) referral to telephone-based smoking cessation counseling, and 3) provision of nicotine replacement therapy. It aims to standardize and optimize the way that vascular surgeons address smoking in their patients.  
 Role: Trial Co-Chair/Principal Investigator  
 Direct Costs: \$100,000
  
19. Tactile Ltd (NCT02015221) 11/01/2014 - 08/28/2015  
*Evaluation of a Dual Action Pneumatic Compression System to assess tolerance and comfort in patients with venous leg ulcers*  
 Role: Principal Investigator  
 Direct Costs: \$73,620
  
20. New England Society for Vascular Surgery Clinical Trials Grant 05/15/2012 – 11/1/2016  
*Open Versus Endovascular Repair of Popliteal Artery Aneurysms (OVERPAR) Trial.* New England Society for Vascular Surgery has bestowed a grant to spearhead a randomized trial through the Vascular Study Group of New England Consortium. The OVERPAR Trial aims

to compare outcomes between open and endovascular repair of popliteal aneurysms in 148 patients.

Role: Trial Co-Chair/Principal Investigator

Direct Costs: \$30,000

21. Tactile Ltd (NCT02680834) 07/01/2016 – 02/1/2017  
*Prospective, randomized, non-inferiority trial comparing a Dual Action Pneumatic Compression System with Multi-Layer Bandaging Systems.*  
Role: Principal Investigator  
Direct Costs: \$88,750.00
22. U01DK082232 09/10/2008 – 06/15/2015  
NIH / NIDDK  
*Determinants of Hemodialysis Arteriovenous Fistula Maturation*  
This was a multicenter observational cohort study of patients with end-stage renal disease undergoing creation of arteriovenous fistulae for hemodialysis. The major goals of the study are to elucidate underlying mechanisms and clinically useful predictors of fistula maturation.  
Role: Co-Investigator
23. NCT 02956993 04/15/2018 – 4/1/2019  
Proteon Inc.  
*Phase I, multi-center, randomized, double-blind, placebo-controlled, dose-escalation study of Vonapanitase administered following angioplasty of a distal popliteal, tibial or peroneal artery in patients with peripheral artery disease.*  
Role: Co-Investigator  
Direct Costs: \$131,310

## TEACHING ACTIVITIES

- |             |   |
|-------------|---|
| 2005 -      | Introduction to Vascular Disease Lecture Series<br>Third Year Surgery Clerkship<br>Boston University School of Medicine   |
| 2006        | Course Co-Director<br>Carotid Artery Stent Training Course<br>(Sponsor: Boston Scientific Corporation)<br>Boston Medical Center   |
| 2006 - 2017 | Course Director<br>Multidisciplinary, CME-accredited, Vascular Educational Curriculum<br>(weekly series of case conferences, journal clubs, techniques and controversies topics in vascular disease management )<br>Boston Medical Center |
| 2008        | Course Director   |

The 23<sup>rd</sup> Annual Smithwick Symposium: Recent Advances in Management of  
Peripheral Arterial Disease  
Boston, MA

2013 - Course Director  
BMC Surgery Bootcamp  
(Annual Boston University School of Medicine elective designed to prepare 4<sup>th</sup>  
year students for surgical internship)

## EDITORIAL ACTIVITIES

### Journal Peer Review

2006 - Journal of Vascular Surgery  
2013 - Distinguished Reviewer  
2006 - Annals of Vascular Surgery  
2008 - Circulation  
2008 - Vascular Medicine  
2011 - Journal of Endovascular Therapy  
2011 - Vascular  
2015 - JAMA Surgery  
2016 - JAMA

### Journal Editorial Board

2009 - International Journal of Angiology  
2014 - Angiology and Vascular Surgery  
2014 - Journal of Vascular Surgery

### Book Editorship

2012 - 2014 **Section Editor**, Rutherford's Vascular Surgery 8<sup>th</sup> edition, Elsevier  
2013 - 2019 **Editor**, Vascular Imaging and Endovascular Interventions, 2<sup>nd</sup> edition, Jaypee  
Brothers Medical Publishers  
2015 - 2016 **Section Editor**, Vascular Surgery: A Global Perspective, Springer  
2017 - **Editor**, Vascular Decision Making: Medical, Endovascular, Surgical, Wolters  
Kluwer (textbook/app in preparation)

## MENTORSHIP

| Students    |                 | Location | Current Position/Academic Rank          |
|-------------|-----------------|----------|---|
| 2007 - 2008 | Deepa Magge     | BUSM     | Surgical Oncologist/Assistant Professor |
| 2012 - 2013 | Vijaya Daniel   | BUSM     | General Surgeon                         |
| 2012 - 2013 | Jennifer Son    | BUSM     | General Surgeon                         |
| 2013 - 2014 | Sarah Rosen     | BUSM     | in training (General Surgery)           |
| 2014 - 2015 | Lili Sadri      | BUSM     | in training (General Surgery)           |
| 2017 - 2018 | Andrew Nimmich  | BUSM     | in training (Vascular Surgery)          |
| 2016 - 2017 | Brianna Krafcik | BMC      | in medical school                       |
| 2017 -      | Thomas Cheng    | BMC      | Research Coordinator                    |

|        |                |      |                   |
|--------|----------------|------|-------------------|
| 2018 - | Mallika Gopal  | BUSM | in medical school |
| 2019 - | Melissa Chua   | BUSM | in medical school |
| 2019 - | Kris Boelitz   | BUSM | in medical school |
| 2019 - | Stephen Raulli | BUSM | in medical school |
| 2019 - | Jason Park     | BUSM | in medical school |

### **Residents**

|             |                   |              |                                      |
|-------------|-------------------|--------------|--------------------------------------|
| 2001 - 2002 | Edward Woodard    | Cedars Sinai | Vascular Surgeon                     |
| 2002 - 2003 | Veronica Artega   | Cedars Sinai | Radiologist/Associate Professor      |
| 2001 - 2003 | Kevin Major       | Cedars Sinai | Vascular Surgeon                     |
| 2004 - 2005 | Karen Woo         | Cedars Sinai | Vascular Surgeon/Associate Professor |
| 2010 - 2012 | Margaret Lauerman | BMC          | Trauma Surgeon/Assistant Professor   |
| 2011 - 2013 | William Tobler Jr | BMC          | Plastic Surgeon                      |
| 2014 - 2017 | Elizabeth King    | BMC          | in training (Vascular Surgery)       |
| 2015 - 2018 | Kimberly Zamor    | BMC          | in training (Vascular Surgery)       |
| 2015 -      | Elica Inagaki     | BMC          | in training (General Surgery)        |
| 2016 -      | Andrew McChesney  | BMC          | in training (General Surgery)        |
| 2017 -      | Nkiruka Arinze    | BMC          | in training (General Surgery)        |
| 2018 -      | Scott Levin       | BMC          | in training (General Surgery)        |
| 2018 -      | Maunil Bhatt      | BMC          | in training (General Surgery)        |
| 2019 -      | Stephanie Talutis | BMC          | in training (General Surgery)        |

### **Fellows**

|             |                  |     |                                      |
|-------------|------------------|-----|--------------------------------------|
| 2005 - 2006 | Felix Vladimir   | BMC | Vascular Surgeon                     |
| 2005 - 2007 | Alisha Oropallo  | BMC | Vascular Surgeon                     |
| 2006 - 2008 | Nasr Wael        | BMC | not in practice                      |
| 2007 - 2009 | Semaan, Elie     | BMC | Vascular Surgeon                     |
| 2008 - 2010 | Joglar, Fernando | BMC | Vascular Surgeon/Assistant Professor |
| 2009 - 2011 | Tony Nguyen      | BMC | Vascular Surgeon                     |
| 2010 - 2012 | Tze-Woei Tan     | BMC | Vascular Surgeon/Assistant Professor |
| 2011 - 2013 | K. Shahmohammedi | BMC | Vascular Surgeon                     |
| 2012 - 2014 | Nick Carruthers  | BMC | Vascular Surgeon/Assistant Professor |
| 2013 - 2015 | Carla Moreira    | BMC | Vascular Surgeon/Assistant Professor |
| 2014 - 2016 | Sebastian Didato | BMC | Vascular Surgeon                     |
| 2015 - 2017 | Sergio Casillas  | BMC | Vascular Surgeon                     |
| 2016 - 2018 | Steven Pike      | BMC | Vascular Surgeon                     |
| 2017 -      | Scott Hardouin   | BMC | Vascular Surgeon                     |
| 2018 -      | Brad Oriel       | BMC | in training                          |
| 2019 -      | Daniel Alfson    | BMC | in training                          |

### **Attending Surgeons**

|        |                  |     |                                      |
|--------|------------------|-----|--------------------------------------|
| 2009 - | Jeffrey Kalish   | BMC | Vascular Surgeon/Associate Professor |
| 2014 - | Jeffrey Siracuse | BMC | Vascular Surgeon/Associate Professor |
| 2017 - | Douglas Jones    | BMC | Vascular Surgeon/Assistant Professor |

### **BIBLIOGRAPHY**

***Journal articles (peer-reviewed)***

1. Karp S, Hwu P, **Farber A**, Restifo NP, and Kriegler M, Mule JJ, Rosenberg SA. *In vivo activity of tumor necrosis factor mutants: Secretory but not membrane-bound TNF $\alpha$  mediates the regression of retrovirally transduced murine tumor.* J Immunol 149: 2076, 1992.
2. Karp S, **Farber A**, Salo JC, Hwu P, Jaffe G, Asher AL, Shiloni E, Restifo NP, Mule JJ, Rosenberg SA. *Cytokine secretion by genetically modified non immunogenic murine fibro sarcoma: Tumor inhibition by IL-2 but not tumor necrosis factor.* J Immunol 150: 896, 1993.
3. **Farber A**, Connors JP, Friedlander RM, Wagner RJ, Powell RJ, Cronenwett JL. *A caspase inhibitor decreases tissue injury in an intestinal ischemia-reperfusion model.* J Vasc Surg 30 (4):752-60, 1999.
4. **Farber A**, Kitzmiller T, Morganelli P, Cronenwett JL, Powell RJ. *A caspase inhibitor decreases oxidized low density lipoprotein-induced apoptosis in bovine endothelial cells.* J Surg Research 85: 323-330, 1999.
5. **Farber A**, Wagner WH, Cossman DV, Cohen JL, Walsh DB, Fillinger MF, Cronenwett JC, Lauterbach SR, Levin PM. *Isolated dissection of the abdominal aorta: Clinical presentation and therapeutic options.* J Vasc Surg 36:205-210, 2002.
6. **Farber A**, Major K, Wagner WH, Cohen JL, Cossman DV, Lauterbach SR, and Levin PM. *A decade of experience with cryopreserved saphenous vein allograft in infrainguinal revascularization: An analysis of 240 grafts.* J Vasc Surg 38(1): 15-21, 2003
7. Major KM, Wilson M, Nishi GK, **Farber A**, Chopra R, Chung A, McVay C, Spivak J, Shabot MM. *The incidence of thromboembolism in the surgical intensive care unit.* Amer Surg 69:857-861, 2003.
8. Wagner WH, Levin PM, Cossman DV, Lauterbach SR, Cohen JL, **Farber A**. *Early experience with radiofrequency ablation of the greater saphenous vein.* Ann Vasc Surg 18: 42-47, 2004.
9. Wagner WH, Cossman DV, **Farber A**, Levin PM, Cohen JL. *Hyperperfusion syndrome after carotid endarterectomy.* Ann Vasc Surg 19(4):479-86, 2005.
10. Woo K, **Farber A**, Doros G, Killeen K, Kohanzadeh S. *Evaluation of the efficacy of the transposed upper arm arteriovenous fistulae: A Single institutional review of 190 basilic and cephalic vein transposition procedures.* J Vasc Surg 46(1):94-99, 2007.
11. Qiao Y, **Farber A**, Semaan E, Hamilton J. *Healing of an asymptomatic carotid plaque ulceration.* Circulation 118:147-8, 2008

12. Semaan E, Hamburg N, Nasr W, Shaw P, Eberhardt R, Woodson J, Doros G, Rybin D, **Farber A.** *Endovascular management of the popliteal artery: Comparison of atherectomy and angioplasty.* Vasc Endovasc Surg 44(1):25-31, 2010
13. Woo K, Doros G, Ng T, **Farber A.** *Comparison of the efficacy of upper arm transposed arteriovenous fistulae and upper arm prosthetic grafts: Analysis of 358 matched procedures.* J Vasc Surg 50:1405-11, 2009
14. **Farber A,** Long BM, Lauterbach SR, Bohannon T, Siegal CL. *What does a vascular surgeon do? Assessment of public knowledge about vascular surgery.* J Vasc Surg 51:771-5, 2010
15. Malikova MA, Doros G, Joglar F, Rybin D, Petros JG, **Farber A.** *A third year surgery clerkship with extensive exposure to vascular surgery improves knowledge about vascular disease and the role of vascular surgeons in its management.* Vasc Endovasc Surg 44(5):361-367, 2010
16. Tan TW, Semaan E, Nasr W, Eberhardt R, Hamburg N, Doros G, Rybin R, Shaw P, **Farber A.** *Endovascular revascularization of symptomatic infra-popliteal arteriosclerotic occlusive disease: Comparison of atherectomy and angioplasty.* Int J Angiology 22(1): 19-24, 2011
17. **Farber A,** Hamburg N, Kalish J, Tan TW, Joglar F, Rybin R, Doros G, Eberhardt R. *Early fasciotomy in patients with extremity vascular injury is associated with decreased risk of adverse limb outcomes: A Review of the National Trauma Data Bank.* Injury 2012;43(9):1486-1491.
18. **Farber A,** Prushik S, Gona P, Shrader P, Pencina M, D'Agostino RB, Murabito JM. *The effect of parental occurrence of intermittent claudication on risk of intermittent claudication in adult offspring: A prospective study of parents and offspring in the Framingham Heart Study.* Am J Cardiol, 2012 Mar 1; 109(5):736-41.
19. Tan TW, Joglar FL, Hamburg NM, Eberhardt RT, Shaw PM, Rybin D, Doros G, **Farber A.** *Limb outcome and mortality in lower and upper extremity arterial injury: A comparison using the National Trauma Data Bank.* Vasc Endovasc Surg 2011; 45(7):592-597.
20. De Martino RR, Brewster LP, Kokkosis AA, Glass C, Boros M, Kreishman P, Kauver D, **Farber A.** *Fatigue, resident training, and patient safety: The perspective of the vascular surgery trainee on new ACGME regulations.* Vasc Endovasc Surg 2012;45(8):697-702.
21. Kalish J, Nguyen T, Hamburg N, Eberhardt R, Rybin D, Doros G, **Farber A.** *Associated venous injury significantly complicates presentation, management, and outcomes of axillo-subclavian artery trauma.* Int J Angiol 2012;21:217-222.

22. Kalish J, Nguyen T, Hamburg N, Eberhardt R, **Farber A**. *The post-exercise common femoral artery doppler waveform improves detection of aorto-iliac occlusive disease*. J Vasc Ultrasound 2012;36(4):1-5.
23. Tan TW, Kalish J, Hamburg N, Rybin D, Doros G, Eberhardt R, **Farber A**. *Shorter duration of femoral-popliteal bypass is associated with decreased surgical site infection and shorter hospital length of stay*. J Am Coll Surg 2012;215:512-518.
24. Kiani S, Aasen J, Holbrook M, Khemka, A, Sharmeen F, LeLeiko RM, Tabit CE, **Farber A**, Eberhardt RT, Gokce N, Vita JA, Hamburg NM. *Peripheral artery disease is associated with severe impairment of vascular function*. Vasc Med. 2013;18(2):72-8.
25. **Farber A**, Tan TW, Kalish JA, Hamburg NM, Eberhardt RT, Rybin D, Doros G, Goodney PP, Cronenwett JL. *Intraoperative use of dextran is associated with cardiac complications after carotid endarterectomy*. J Vasc Surg 2013;57:635-642.
26. Lantis JC, Marston WA, **Farber A**, Kirsner RS, Zhang Y, Lee TD, Cargill DI, Slade B. *The influence of patient and wound variables on healing of venous leg ulcers in a randomized controlled trial of growth arrested allogeneic keratinocytes and fibroblasts*. J Vasc Surg 2013; 58 (2):433-9.
27. Tan TW, Kalish JA, **Farber A**, Hamburg NM, Eberhardt RT, Rybin D, Doros G, Eldrup-Jorgensen J, Goodney PP, Cronenwett JL. *Blood transfusion for lower extremity bypass is associated with increased wound infection and graft thrombosis*. J Am Coll Surg 2013;216:1005-1014.
28. De Martino RR, Goodney PP, Nolan BN, Robinson WP, **Farber A**, Patel VI, Stone DH, Cronenwett JL. *Optimal selection of patients for elective abdominal aortic aneurysm repair based on life expectancy*. J Vasc Surg 2013;58(3):589-95.
29. Lauerman MH, Rybin D, Doros G, Kalish J, Hamburg N, Eberhardt R, **Farber A**. *Characterization and outcomes of iliac vessel injury in the 21<sup>st</sup> century: A review of the National Trauma Data Bank*. Vasc Endovasc Surg 2013;47(5):325-30.
30. Tan TW, Eslami MH, Kalish JA, Eberhardt RT, Doros G, Goodney PP, Cronenwett JL, **Farber A**. *The need for treatment of hemodynamic instability following carotid endarterectomy is associated with increased perioperative and one-year morbidity and mortality*. J Vasc Surg 2014;59:16-24.
31. **Farber A**, Belenky A, Malikova M, Karmeli R, Brenner O, Migdal M, Kim D. *The evaluation of a novel technique to treat saphenous vein incompetence: Preclinical animal study to evaluate safety and efficacy of new vein occlusion device*. Phlebology 2014;29:16-24.



32. Daniel VT, Madenci AL, Nguyen LL, Eslami MH, Kalish JA, **Farber A**, McPhee JT. *Contemporary comparison of supra-aortic trunk surgical reconstructions for occlusive disease.* J Vasc Surg 2014;59(6): 1577-1582.
33. Tan TW, Rybin, D, Doros G, Kalish, JA, **Farber A**, Eslami, MH. *Observation and surgery are associated with low risk of amputation for blunt brachial artery injury in pediatric patients.* J Vasc Surg. 2014 Aug; 60(2):443-7.
34. Tan TW, Rybin D, Kalish JA, Doros G, Hamburg N, Schanzer A, Cronenwett JL, **Farber A**. *Routine use of completion imaging after infrainguinal bypass is not associated with higher bypass graft patency.* J Vasc Surg 2014 Sep; 60(3): 678-685.e2
35. Kalish J, **Farber A**, Homa K, Trinidad M, Beck A, Wyers M, Davies MG, Chiriano J, Tracci M, Kraiss L, Cronenwett. *Factors associated with surgical site infection after lower extremity bypass in the SVS Vascular Quality Initiative.* J Vasc Surg 2014 Nov; 60(5):1238-1246.
36. Carruthers TN, **Farber A**, Rybin D, Doros G, Eslami MH. *Interventions on the superficial venous system for chronic venous insufficiency by surgeons in the modern era: An analysis of ACS-NSQIP.* Vasc Endovascular Surg. 2014 Oct; 48(7-8):482-90.
37. Kalish J, Sloan M, Sarosiek S, Marks H, Moreira C, Hamburg N, Vilvendhan R, **Farber A**. *Tracking breeds success: Improved retrieval rates of Inferior Vena Cava Filters with minimal dedication of resources.* J Vasc Surg Venous Lymphat Disord. 2014 Jan; 2(1):117.
38. Chong CC, Tan TW, Abreo K, Pahilan ME, Rybin D, Doros G, Zhang WW, **Farber A**. *Laparoscopic peritoneal dialysis catheter placement is associated with decreased deep organ infection and reoperation.* Clin Nephrol Clin Nephrol. 2015 Mar; 83(3):161-6.
39. Eslami MH, Rybin D, Doros G, **Farber A**. *Care of patients undergoing vascular surgery at safety net public hospitals is associated with higher cost but similar mortality to non-safety net hospitals.* J Vasc Surg 2014 Dec 60 (6): 1627-1634.
40. Eslami MH, Doros G, Goodney PP, Eldrup-Jorgenson J, Cronenwett JL, Malikova M, **Farber A**. *Using Vascular Quality Initiative as a platform for organizing multicenter, prospective, randomized clinical trials: OVERPAR Trial.* Ann Vasc Surg. 2015 Feb; 29(2):278-85.
41. Eslami MH, Rybin D, Doros G, **Farber A**. *Open repair of asymptomatic popliteal artery aneurysm is associated with better outcomes than endovascular repair.* J Vasc Surg. 2015 Mar; 61(3):663-9.
42. Eslami MH, Rybin D, Doros G, Mcphee JT, **Farber A**. *Mortality of acute mesenteric ischemia remains unchanged despite significant increase in utilization of endovascular techniques.* Vascular 2016 Feb;24(1):44-52.

43. Kalish J, Eslami M, Gillespie D, Schermerhorn M, Rybin D, Gheorghe Doros, **Farber A**. *Routine use of ultrasound guidance in femoral arterial access for peripheral vascular intervention decreases groin hematoma rates*. J Vasc Surg 2015;61(5):1231-8.
44. **Farber A**, Imrey PB, Huber TS, Kaufman JM, Kraiss LW, Larive B, Li L, Feldman HI, and the HFM Study Group. *Multiple pre-operative and intra-operative factors predict early fistula thrombosis in the Hemodialysis Fistula Maturation Study*. J Vasc Surg. 2016 Jan; 63(1):163-170.e6.
45. **Farber A**, Tan TW, Hu, Dember LM, Gerald Beck GJ, Dixon B, Kusek JW, Feldman HI *The effect of location and configuration on forearm and upper arm hemodialysis arteriovenous grafts*. J Vasc Surg. 2015 Nov; 62(5):1258-65.
46. Moreira CC, **Farber A**, Rybin D, Doros G, Kalish J, Eberhardt RT, Siracuse J, Hamburg NM. *Racial differences in treatment approaches and mortality following arterial trauma*. Vasc Endovascular Surg. 2015 Oct; 49(7):180-7.
47. Malikova M, Shifflett L, **Farber A**. *Implementation of strategic management tools improves wound care clinical trial outcomes*. Clin Invest 2015 Jul; 5(7):653-64.
48. Eslami MH, Rybin D, Doros G, **Farber A**. *The Association of publication of Center for Medicaid and Medicare Services Guidelines for Carotid Artery Angioplasty and Stenting (CAS) and CREST results on the utilization of CAS in carotid revascularization*. Ann Vasc Surg. 2015 Nov; 29(8):1606-13.
49. Tan TW, Eslami MH, Rybin D, Doros G, Zhang W, **Farber A**. *Blood transfusion is associated with increased risk of perioperative complications and prolonged hospital length of stay among patients undergoing amputation*. Surgery. 2015 Dec; 158(6):1609-16.
50. Eslami MH, Rybin, Doros G, Kalish JA, **Farber A**. *Comparison of a Vascular Study Group of New England risk prediction model with established risk prediction models of in-hospital mortality after elective abdominal aortic aneurysm repair*. J Vasc Surg. 2015 Nov; 62(5):1125-1133.e2.
51. Carruthers TN, Shamohammadi K, **Farber A**, Rybin D, Doros G, Mcphee JT, Kalish JA, Eslami MH. *Perspectives on endovascular training in traditional 5+2 vascular surgery fellowship training programs*. Vascular. 2016 Apr;24(2):134-43.
52. Nzara R, Rybin D, Doros G, Didato S, **Farber A**, Eslami MH, Kalish JA, Siracuse JJ. *Perioperative outcomes in patients requiring iliac conduits or direct access for endovascular abdominal aortic aneurysm repair*. Ann Vasc Surg. 2015 Nov; 29(8):1548-53.
53. DiDato S, **Farber A**, Rybin D, Kalish JA, Eslami MH, Moreira CC, Shah NK, Siracuse JJ. *The effect of trainee involvement on perioperative outcomes of abdominal aortic aneurysm repair*. J Vasc Surg. 2016 Jan; 63(1):16-22.

54. Tan TW, Eslami M, Rybin D, Doros G, Zhang WW, **Farber A**. *Outcomes of patients with type I endoleak at completion of endovascular abdominal aneurysm repair*. J Vasc Surg. 2016 Jun; 63(6):1420-7.
55. Shah NK, **Farber A**, Kalish JA, Eslami M, Segupta A, Doros G, Rybin D, Siracuse JJ. *Occurrence of never events after major open vascular surgery procedures*. J Vasc Surg. 2016 Mar; 63(3):738-745.
56. Moreira CC, **Farber A**, Kalish JA, Eslami MH, DiDato S, Rybin D, Doros G, Siracuse JJ. *The effect of anesthesia type on major lower extremity amputation in functionally impaired elderly patients*. J Vasc Surg. 2016 Mar; 63(3):696-701.
57. Krafcik BM, Sachs TE, **Farber A**, Eslami MH, Kalish JA, Peacock M, Shah NK, Siracuse JJ. *Assessment of open operative vascular surgical experience among general surgery residents*. J Vasc Surg. 2016 Apr; 63(4):1110-1115.
58. Siracuse JJ, Menard M, Eslami MH, Robinson William, Eberhardt RT, Hamburg NM, Kalish JA, **Farber A**. *Comparison of open and endovascular treatment of patients with critical limb ischemia in the Vascular Quality Initiative*. J Vasc Surg 2016 Apr;63(4):958-965.
59. Spangler E, Brooke, BS, Beck AW, Hoel A, **Farber A**, Goodney PP. *Design and initial enrollment in the Vascular Physicians Offer and Report (VAPOR) Trial*. J Vasc Surg. 2016 Apr; 63(4):1121-1125.
60. Newhall K, Burnette MF, Brooke BS, Schanzer A, Tan TW, Flocke S, **Farber A**, Goodney PP. *Smoking cessation counseling in vascular surgical practice using the results of interviews and focus groups in the Vascular Surgeon offer and report smoking cessation pilot trial*. J Vasc Surg. 2016 Apr; 63(4):1011-1017.
61. Eslami MH, Rybin D, Doros G, **Farber A**. *An externally validated robust risk predictive model of adverse outcomes after carotid endarterectomy*. J Vasc Surg 2016 Feb; 63(2):345-54.
62. Inagaki E, **Farber A**, Eslami MH, Siracuse JJ, Rybin DV, Sarosiek S, Sloan JM, Kalish J. *Improving the retrieval rate of inferior vena cava filters with a multidisciplinary team approach*. J Vasc Surg: Venous and Lym Dis. 2016 Jul;4(3):276-82.
63. Siracuse JJ, Schermerhorn ML, Meltzer AJ, Eslami MH, Kalish JA, Rybin D, Doros G, **Farber A**. *Comparison of outcomes after endovascular and open repair of abdominal aortic aneurysms in low risk patients*. Br J Surg. 2016 Jul;103(8):989-94.
64. Krafcik B, **Farber A**, Eslami MH, Kalish JA, Rybin D, Doros G, Shah, N, Siracuse JJ. *The role of Model of End Stage Liver Disease (MELD) Score in predicting outcomes for lower extremity bypass*. J Vasc Surg. 2016 Jul;64(1):124-130.

65. Moreira CC, Leung AD, **Farber A**, Rybin D, Doros G, Siracuse JJ, Kalish JA, Eslami MH. *Alternative conduit for infrageniculate bypass in patients with critical limb ischemia*. J Vasc Surg. 2016 Jul;64(1):131-139.
66. Menard M, **Farber A**, Assmann S, Choudry N, Conte M, Creager M, Dake M, Jaff M, Kaufman J, Powell R, Reid D, Siami FS, Sopko G, White C, Rosenfield K. *Design and rationale of the BEST-CLI (Best Endovascular versus best Surgical Therapy for patients with Critical Limb Ischemia) Trial*. J Am Heart Assoc. 2016 Jul 8;5(7):e003219.
67. Eslami MH, Zhu CK, BS, Rybin,D, Doros, G, Siracuse JJ, **Farber A**. *Simple predictive model of early failure among patients undergoing first time arteriovenous fistula creation*. Ann Vasc Surg. 2016 Aug;35:46-52.
68. Krafcik B, **Farber A**, Eslami MH, Kalish JA Rybin D, Doros G, King EG, Siracuse JJ. *The role of the Model of End Stage Liver Disease (MELD) score in predicting outcomes of carotid endarterectomy*. Vasc Endovasc Surg. 2016 Aug; 50(6):380-4.
69. Huber TS, Larive B, Imrey PB, Radeva MK, Kaufman JM, Kraiss LW, **Farber A**, Berceci SA. *Access related hand ischemia and the Hemodialysis Fistula Maturation Study*. J Vasc Surg. 2016 Oct;64(4):1050-8.
70. Jarraya M, Simmons S, **Farber A**, Teytelboym O, Naggara N, Guerhazi A. *Uncommon diseases of the popliteal artery: Pictorial review*. Insights Imaging. 2016 Oct;7(5):679-88.
71. Hicks CW, Najafian A, **Farber A**, Menard MT, Malas MB, MHS, Black III JH, Abularrage CJ. *Diabetes does not worsen outcomes following infrageniculate bypass or endovascular intervention for patients with critical limb ischemia*. J Vasc Surg 2016 Dec; 64(6):1667-1674.
72. Eslami MH, Rybin D, Doros G, **Farber A**. *Description of a risk predictive model of 30-day post-operative mortality after elective abdominal aortic aneurysm repair*. J Vasc Surg. 2017 Jan;65(1):65-75. PMID: 27720320.
73. Motaganahalli RL, Smeds MR, Harlander-Locke MP, Lawrence PF, Fujimura N, DeMartino RR, De Caridi G, Munoz A, Shalhub S, Shin SH, Amankwah KS, Gelabert HA, Rigberg DA, Siracuse JJ, **Farber A**, Debus ES, Behrendt C, Joh JH, Wittgen CM. *A multi-institutional experience in adventitial cystic disease*. J Vasc Surg. 2017 Jan;65(1):157-61. PMID: 27751735.
74. Newhall K, Suckow BD, Spangler E, Brooke BS, , Schanzer A, Tan TW, Burnette MF Edelen MO, **Farber A**, Goodney PP. *Impact and duration of brief surgeon-delivered smoking cessation advice on attitudes regarding nicotine dependence and tobacco harms for patients with peripheral arterial disease*. Ann Vasc Surg. 2017 Jan;38:113-121. PMID: 27521828.

75. Tahhan G, **Farber A**, Shah NK, Krafchik B, Kalish JA, Peacock MR, Siracuse JJ. *Characterization of planned and unplanned thirty day readmissions following vascular surgical procedures*. Vasc Endovascular Surg. 2017 Jan; 51(1):17-22. PMID: 28100157.
76. Hicks CW, Najafian A, **Farber A**, Menard MT, Malas MB, MHS , Black III JH, Abularrage CJ. *Below-knee endovascular interventions have better outcomes compared to open bypass for patients with critical limb ischemia*. Vasc Med. 2017 Feb;22(1):28-34. PMID: 27928034.
77. Casillas-Berumen S, Sadri L, **Farber A**, Eslami MH, Kalish JA, Rybin D, Doros G, Siracuse JJ. *Morbidity and mortality after emergent lower extremity embolectomy*. J Vasc Surg. 2017 Mar; 65(3):754-759. PMID: 28236918.
78. Siracuse JJ, Krafchik BM, **Farber A**, Kalish JA, McChesney A, Rybin D, Doros G, Eslami MH. *Contemporary open repair of ruptured abdominal aortic aneurysms*. J Vasc Surg. 2017 Apr;65(4):1023-8. PMID: 27986483.
79. Goodney PP, Spangler EL, Newhall K, Brooke BS, Schanzer A, Tan TW, Beck AW, Hallett JH, MacKenzie TA, Edelen MO, Hoel AW, Rigotti NA, **Farber A**. *Feasibility and pilot efficacy of a brief smoking cessation intervention delivered by vascular surgeons in the Vascular Physician Offer and Report (VAPOR) Trial*. J Vasc Surg. 2017 Apr; 65(4):1152-1160.e2. PMID: 28190719.
80. Siracuse JJ, Van Orden K, Kalish JA, Eslami MH, Schermerhorn ML, Patel VI, Rybin D, **Farber A**. *Endovascular treatment of the common femoral artery in the Vascular Quality Initiative*. J Vasc Surg. 2017 Apr;65(4):1039-46. PMID: 28041804.
81. Peacock MR, **Farber A**, Eslami MH, Kalish JA, Rybin D, Doros G, Shah N, Siracuse JJ. *Hypoalbuminemia predicts perioperative morbidity and mortality after infrainguinal lower extremity bypass for critical limb ischemia*. Ann Vasc Surg. 2017 May;41:169-175. PMID: 28242402.
82. Peacock MR, Shah NK, **Farber A**, Lee S, Kalish JA, Rybin D, Doros G, Siracuse JJ. *Index complications predict secondary complications after infrainguinal lower extremity bypass for critical limb ischemia*. J Vasc Surg. 2017 May;65(5):1344-1353. PMID: 28222984.
83. Siracuse JJ, Kalish JA, Eslami MH, Rybin D, **Farber A**. *Thirty and ninety day hospital readmission after outpatient upper extremity hemodialysis access creation*. J Vasc Surg. 2017 May;65:1376-82. PMID: 28222988.
84. Lu K, **Farber A**, Schermerhorn ML, Patel V, Kalish JA, Rybin D, Doros G, Siracuse JJ. *The Effect of Ambulatory Status on Outcomes of Percutaneous Vascular Interventions and Lower Extremity Bypass for Critical Limb Ischemia in the Vascular Quality Initiative*. J Vasc Surg. 2017 Jun;65(6):1706-1712. PMID: 28216361.

85. Kim GY, Lawrence PF, Moridzadeh RS, Zimmerman K, Munoz A, Luna-Ortiz K, Oderich GS, de Francisco J, Ospina J, Huertas S, de Souza LR, Bower TC, Farley S, Gelabert HA, Kret MR, Harris EJ, De Caridi G, Spinelli F, Smeds MR, Liapis CD, Kakisis J, Papapetrou AP, Debus ES, Behrendt CA, Kleinspehn E, Horton JD, Mussa FF, Cheng SWK, Morasch MD, Rasheed K, Bennett ME, Bismuth J, Lumsden AB, Abularrage CJ, **Farber A**. *New predictors of complications in carotid body tumor resection*. J Vasc Surg. 2017 Jun; 65(6):1673-1679. PMID: 28527929.
86. Inagaki E, **Farber A**, Eslami MH, Kalish JA, Rybin D, Doros G, Peacock MR, Siracuse JJ. *Preoperative hypoalbuminemia is associated with poor clinical outcomes after open and endovascular abdominal aortic aneurysm repair*. J Vasc Surg. 2017 Jul;66(1):53-63. PMID: 28216349.
87. Salzler GG, **Farber A**, Rybin D, Doros G, Siracuse JJ, Eslami MH. *The association of Carotid Revascularization Endarterectomy versus Stent Trial (CREST) and Centers for Medicare and Medicaid Services Carotid Guideline Publication on utilization and outcomes of carotid stenting among "high-risk" patients*. J Vasc Surg. 2017 Jul;66(1):104-111. PMID: 28502543.
88. Tan TW, Eslami MH, Rybin D, Doros G, Zhang WW, **Farber A**. *Outcomes of endovascular and open surgical repair of ruptured abdominal aortic aneurysms in elderly patients*. J Vasc Surg. 2017 Jul; 66(1):64-70 PMID: 28216354.
89. King EG, **Farber A**, Rybin D, Doros G, Kalish JA, Eslami MH, Siracuse JJ. *Pre-operative risk factors predict protracted hospital length of stay after elective endovascular abdominal aortic aneurysm repair*. Ann Vasc Surg. 2017 Aug; 43:73-78. PMID: 28389289.
90. Robich MP, Krafcik BM, Shah NK, **Farber A**, Rybin D, Siracuse JJ. *Analysis of "Never events" following adult cardiac surgical procedures in the United States*. J Cardiovasc Surg (Torino). 2017 Oct;58(5):755-762. PMID: 28320201.
91. Alpers CE, Imrey PB, Hudkins KL, Wietecha TA, Radeva M, Allon M, Cheung AK, Dember LM, Roy-Chaudhuri P, Shiu Y-T, Terry CM, **Farber A**, Beck GJ, Feldman HI, Kusek JW, Himmelfarb J and the Hemodialysis Fistula Maturation Study Group. *Histopathology of veins obtained at hemodialysis arteriovenous fistula creation surgery*. J Am Soc Nephrol. 2017 Oct; 28(10):3076-3088. PMID: 28724774.
92. Lee SY, Peacock MR, **Farber A**, Shah NK, Eslami MH, Kalish JA, Rybin D, Komshian S, Siracuse JJ. *Perioperative infections after open abdominal aortic aneurysm repair lead to increased risk of subsequent secondary complications*. Ann Vasc Surg. 2017 Oct;44:203-210. PMID: 28483623.
93. Inagaki E, **Farber A**, Kalish JA, Siracuse JJ, Zhu C, Rybin D, Doros G, Eslami MH. *Role of language discordance in complication and readmission rate after infrainguinal bypass*. J Vasc Surg. 2017 Nov;66(5):1473-78. PMID: 28625669.

94. Avgerinos ED, **Farber A**, Abou Ali AN, Rybin D, Doros G, Eslami MH. *Early carotid endarterectomy performed 2-5 days after the onset of neurological symptoms leads to comparable results to carotid endarterectomy performed at later time points.* J Vasc Surg. 2017 Dec; 66(6):1719-1726. PMID: 28830709.
95. Krafcik BM, Komshian S, Lu K, Roberts L, **Farber A**, Kalish JA, Rybin D, Siracuse JJ. *Short and long-term readmissions rates after infrainguinal bypass in a safety net hospital are higher than expected.* J Vasc Surg. 2017 Dec;66(6):1786-1791. PMID: 28965800.
96. Eslami MH, Rybin D, Doros G, Siracuse JJ, **Farber A**. *External validation of Vascular Study Group of New England risk predictive model of mortality after elective abdominal aorta aneurysm repair in Vascular Quality Initiative and comparison against established models.* J Vasc Surg. 2018 Jan;67(1):143-150. PMID: 28807384.
97. Casillas-Berumen S, Rojas-Miguez FA, **Farber A**, Komshian S, Kalish JA, Rybin D, Doros G, Siracuse JJ. *Patient and aneurysm characteristics predicting prolonged length of stay after elective open AAA repair in the endovascular era.* Vasc Endovascular Surg. 2018 Jan;52(1):5-10. PMID: 29121844.
98. Krafcik BM, **Farber A**, MD; Eberhardt RT, Kalish JA, Rybin D, Doros G, Pike S, Siracuse JJ. *Preoperative statin and antiplatelet use does not affect perioperative outcomes after carotid endarterectomy.* Ann Vasc Surg. 2018 Jan;46:43-52. PMID: 29100876.
99. Krafcik BM, Cheng TW, **Farber A**, Kalish JA, Rybin D, Doros G, Siracuse J. *Perioperative outcomes after re-operative carotid endarterectomy are worse than expected.* J Vasc Surg. 2018 Mar;67(3):793-798. PMID: 29042076.
100. Cheng TW, **Farber A**, Kalish JA, Jones DW, Myriam Castagne M, Rybin D, Raulli, SJ, Siracuse JJ. *Carotid endarterectomy performed before the weekend is associated with increased length of stay.* Ann Vasc Surg. 2018 Apr;48:119-126. PMID: 29217437.
101. Inagaki E, **Farber A**, Kalish JA, Eslami MH, Siracuse JJ, Eberhardt RT, Rybin D, Doros G, Hamburg N. *Outcomes of peripheral vascular interventions in select patients with lower extremity acute limb ischemia.* J Am Heart Assoc. 2018 Apr 12;7(8). PMID: 29650705.
102. Allon M, Imrey PB, Cheung AK, Radeva M, Alpers CE, Beck GJ, Dember LM, **Farber A**, Greene T, Himmelfarb J, Huber TS, Kaufman JS, Kusek JW, Roy-Chaudhury P, Robbin ML, Vazquez MA, Feldman HI. *Relationships Between Clinical Processes and Arteriovenous Fistula Cannulation and Maturation: A Multicenter Prospective Cohort Study.* Am J Kidney Dis. 2018 May;71(5):677-689. PMID: 29398178.
103. Komshian S, Cheng TW, **Farber A**, Schermerhorn ML, Kalish JA, Rybin D, Jones DW, Siracuse JJ. *Retrograde popliteal access to treat femoro-popliteal artery occlusive disease.* J Vasc Surg. 2018 Jul;68(1):161-167. PMID: 29503002.

104. Siracuse JJ, **Farber A**, Kalish JA, Jones DW, Rybin D, Doros G, Scali ST, Schermerhorn ML. *Comparison of access type on perioperative outcomes after endovascular aortic aneurysm repair*. J Vasc Surg. 2018 Jul;68(1):91-99. PMID: 29342431.
105. Kalesan B, Cheng TW, **Farber A**, Zuo Y, Kalish JA, Jones DW, Siracuse JJ. *Readmissions after thoracic endovascular aortic repair*. J Vasc Surg. 2018 Aug;68(2):372-382. PMID: 29506946.
106. Inagaki E, **Farber A**, Siracuse JJ, Mell MW, Rybin D, Doros G, Jeffrey Kalish JA. *Routine Use of ultrasound guidance in femoral arterial access for peripheral vascular intervention decreases groin hematoma rates in high-volume surgeons*. Ann Vasc Surg. 2018 Aug;51:1-7. PMID: 29655812.
107. Van Orden K, **Farber A**, Schermerhorn ML, Goodney P, Kalish JA, Jones DW, Rybin D, Siracuse JJ. *Local anesthesia for percutaneous endovascular aortic aneurysm repair is associated with fewer pulmonary complications*. J Vasc Surg. 2018 Oct;68(4):1023-1029. PMID: 29602472.
108. Eslami MH, Reitz KM, Rybin D, Doros G, **Farber A**. *Improved Access to healthcare in Massachusetts after 2006 Massachusetts Healthcare Reform Law is associated with a significant decrease in mortality among vascular surgery patients*. J Vasc Surg. 2018 Oct;68(4):1193-1202. PMID: 29615354.
109. King EG, Oransky I, Sachs TE, **Farber A**, Flynn DB, Abritis A, Kalish JA, Siracuse JJ. *Analysis of retracted articles in the surgical literature*. Am J Surg. 2018 Nov;216(5):851-855. PMID: 29229380.
110. Arinze N, **Farber A**, Sachs TE, Patts G, Kalish JA, Kuhn A, Kastotakis G, Siracuse JJ. *The effect of statin use and intensity on stroke and myocardial infarction after carotid endarterectomy*. J Vasc Surg. 2018 Nov;68(5):1398-1405. PMID: 29685507.
111. O'Donnell TFX, Deery SE, Schermerhorn ML, Siracuse JJ, Bertges DJ, **Farber A**, Lancaster RT, Patel VI. *The Impact of Perioperative Ankle-Brachial Index and Clinical Status on Outcomes Following Lower Extremity Bypass*. Ann Vasc Surg. 2018 Nov;53:139-147. PMID: 29885428.
112. Siracuse JJ, Paracha M, **Farber A**, Rybin D, Doros G, Tseng J, McAneny D, Sachs T. *Never events after hepatopancreatobiliary operations*. Am J Surg. 2018 Dec;216(6):1129-1134. PMID:30146274.
113. Osteguín V, Cheng TW, **Farber A**, Eslami M, Kalish JA, Jones DW, Rybin D, Raulli SJ, Siracuse JJ. *Emergency department utilization after lower extremity bypass for critical limb ischemia*. Ann Vasc Surg. 2019 Jan;54:134-143. PMID: 29778609.
114. Komshian S, **Farber A**, Patel VI, Goodney PP, Schermerhorn ML, Blazick EA, Jones DW, Rybin D, Doros G, Siracuse JJ. *Patients with end-stage renal disease have poor outcomes*



- after endovascular abdominal aortic aneurysm repair. J Vasc Surg. 2019 Feb;69(2):405-413. PMID: 29945838.*
115. Raulli SJ, Cheng TW, **Farber A**, Eslami MH, Kalish JA, Jones DW, Rybin D, Nuhn M, Gautam A, Siracuse JJ. *Intraoperative heparin use during upper extremity arteriovenous access creation does not affect outcomes. Ann Vasc Surg. 2019 Feb;55:216-221. PMID: 30217706.*
  116. Eslami MH, Saadedin ZA, Rybin D, Doros, G, Siracuse JJ, **Farber A**. *Association of Frailty Index with peri-operative mortality and in-hospital morbidity after elective lower extremity bypass. J Vasc Surg. 2019 Mar;69(3):863-874. PMID: 30527215.*
  117. Hossain S, Leblanc D, **Farber A**, Power AH, DeRose G, Duncan A, Dubois L. *Infrainguinal bypass following failed endovascular intervention compared with primary bypass: A systematic review and metanalysis. Eur J Vasc Endovasc Surg. 2019 Mar;57(3):382-391. PMID: 30393063.*
  118. Tan TW, Siracuse JJ, Brooke BS, Baril DT, Woo K, Rybin D, Doros G, **Farber A**. *Comparison of one-stage and two-stage upper arm brachio basilic arteriovenous fistula in the Vascular Quality Initiative. J Vasc Surg. 2019 Apr;69(4):1187-1195. PMID: 30301685.*
  119. Siracuse JJ, **Farber A**, Cheng TW, Raulli SJ, Jones DW, Kalish JA, Smeds MR, Rybin D, Schermerhorn ML. *Common femoral artery antegrade and retrograde approaches have similar access site complications. J Vasc Surg. 2019 Apr;69(4):1160-1166. PMID: 30527937.*
  120. Eslami MH, Saadedin ZA, Rybin D, Eslami PA, Avgerinos EA, Siracuse JJ, **Farber A**. *Trends and Outcomes of Pediatric Vascular Injuries in the United States: an Analysis of the National Trauma Data Bank. Ann Vasc Surg. 2019 Apr;56:52-61. PMID: 30476614.*
  121. Siracuse JJ, **Farber A**, James T, Cheng TW, Zuo Y, Kalish JA, Jones DW, Kalesan B. *Readmissions after Firearm Injury Requiring Vascular Repair. Ann Vasc Surg. 2019 Apr;56:36-45. PMID: 30500659.*
  122. Cheng TW, **Farber A**, Rajani RR, Jones DW, Flynn D, Rybin D, Doros G, Kalish JA, Meltzer AJ, Siracuse JJ. *National criteria for academic appointment in vascular surgery. J Vasc Surg. J Vasc Surg. 2019 May;69(5):1559-1565.*
  123. Siracuse JJ, Cheng TW, **Farber A**, James T, Zuo Y, Kalish JA, Jones DW, Kalesan B. *Vascular repair after firearm injury is associated with increased morbidity and mortality. J Vasc Surg. 2019 May;69(5):1524-1531.*
  124. Roberts L, **Farber A**, Jones DW, Woo K, Eslami MH, Simons J, Malas M, Tan TW, Rybin D, Siracuse, JJ. *Tapered arteriovenous grafts do not provide significant advantage over non-tapered grafts in upper extremity dialysis access. J Vasc Surg. 2019 May;69(5):1552-1558. PMID: 30583896.*

125. Powell R, Menard M, **Farber A**, Kenneth Rosenfeld K, Goodney P, Gray B, Lookstein R, Pena C, Schermerhorn ML. *Comparison of Specialties Participating in the BEST-CLI Trial to Specialists Treating Peripheral Arterial Disease Nationally*. J Vasc Surg. 2019 May;69(5):1505-1509.
126. Cheng TW, **Farber A**, Eslami MH, Kalish JA, Jones DW, Rybin D, Siracuse JJ. *Removal of Infected Arteriovenous Grafts is Morbid and Many Patients Do Not Receive a New Access Within One Year*. J Vasc Surg. 2018 Dec 24. PMID: 30591289.
127. Siracuse JJ, Cheng TW, A, Levin SR, Jones DW, Malas MB, Kalish JA, Rybin D, **Farber A**. *Snuffbox arteriovenous fistulas have similar outcomes and patency as wrist arteriovenous fistulas*. J Vasc Surg. 2019 Mar 02. PMID:30837175.
128. Arinze NV, Gregory A, Francis JM, **Farber A**, Chitalia VC. *Unique aspects of peripheral arterial disease in patients with chronic kidney disease*. Vasc Med.2019 Mar 01; 1358863X18824654. PMID: 30823859.
129. Arinze N, **Farber A**, Levin SR, Cheng TW, Jones DW, Siracuse CG, Patel V, Rybin D Doros G, Siracuse JJ. *The effect of the duration of preoperative smoking cessation timing on outcomes after elective open abdominal aortic aneurysm repair and lower extremity bypass*. J Vasc Surg 2019 May 27. PMID: 31147124
130. Levin SR, **Farber A**, Cheng TW, Jones DW, Rybin D, Kalish JA, Bennett KM, Arinze N, Siracuse JJ. *The Majority of Patients who Suffer a Thirty-Day Postoperative Stroke after Carotid Endarterectomy Initially Experience Disability*. J Vasc Surg 2019 May 05. PMID: 31068266
131. Saadeddin ZM, Rybin D, Doros G, Siracuse JJ, **Farber A**, Eslami MH. *Comparison of Early and Late Postoperative Outcomes After Supra-inguinal Bypass for Aortoiliac Occlusive Disease*. Eur J Vasc Endovasc Surg. 2019 Aug 19. PMID: 31439432.
132. Jones DW, Deery S, Schneider D, Rybin D, Siracuse JJ, **Farber A**, Schermerhorn ML. *Differences in Patient Selection and Outcomes Based on AAA Diameter Thresholds in the Vascular Quality Initiative*. J Vasc Surg (in press)
133. Eslami MH, Saadeddin Z, **Farber A**, Fish L, Avgerinos ED, Makaroun MS. *External Validation of the VSGNE Carotid Endarterectomy Risk Predictive Model Using an Independent US National Surgical Database*. J Vasc Surg. 2019 Oct 29. PMID: 31676184.
134. Humbarger O, Siracuse JJ, Rybin D, Stone SH, Goodney PP, Schermerhorn ML, **Farber A**, Jones DW. *Broad variation in prosthetic conduit utilization for femoral popliteal bypass is not justified based on contemporary outcomes favoring autologous great saphenous vein*. J Vasc Surg May 27. PMID: 31147137.

135. Pike SL, **Farber A**, Arinze N, Levin S, Cheng TW, Jones DW, Tan TW, Malas M, Rybin D, Siracuse JJ. *Patients with lower extremity dialysis access have poor primary patency and survival.* J Vasc Surg 2019 May 27. PMID: 31147128.
136. Levin SR, **Farber A**, Cheng TW, Arinze N, Jones DW, Kalish JA, Rybin D, Siracuse JJ. *Risk assessment of significant upper extremity arteriovenous graft infection in the Vascular Quality Initiative.* J Vasc Surg. 2019 Jul 18. PMID: 31327606.
137. Levin AR, **Farber A**, Bertges DJ, Ferris M, Cheng TW, Arinze N, Jones DW, Rybin D, Siracuse JJ. *Larger sheath size for infrainguinal endovascular intervention is associated with minor but not major morbidity or mortality.* Ann Vasc Surg 2019 Jun 11. PMID: 31200055.
138. Bluemn EG, Flahive JM, **Farber A**, Bertges DJ, Goodney PP, Eldrup-Jorgensen J, Schanzer A, Simons JP. *Analysis of thirty-day readmission following infrainguinal bypass.* Ann Vasc Surg. 2019 Jul 23. PMID: 31349054.
139. Hardouin S, **Farber A**, Kalish JA, Cheng TW, Jones DW, Malas, MB, Rybin D, Oriel BS, Plauche L, Siracuse, JJ. *Axillary-bi-femoral and axillary-uni-femoral artery grafts have similar perioperative outcomes and patency.* J Vasc Surg (in press)
140. Arinze N, **Farber A**, Levin SR, Cheng TW, Jones DW, Patel VI, Kalish J, Rybin D, Doros G, Siracuse JJ. *Perioperative outcomes after lower extremity bypass and peripheral vascular interventions in patients with morbid and superobesity.* J Vasc Surg. 2019 Aug 20. PMID: 31443977.
141. **Farber A**, Cheng TW, Nimmich A, Jones DW, Kalish JA, Eslami MH, Hardouin S, Siracuse JJ. *Femoral vein transposition is a durable hemodialysis access for patients who have exhausted upper extremity options* J Vasc Surg 2019 Sep 03. PMID: 31492614.
142. Mohapatra A, Liang NL, Makaroun M, Schermerhorn ML, **Farber A**, Eslami MH. *Risk factors for mortality after endovascular repair for blunt thoracic aortic injury* J Vasc Surg. 2019 Sep 13. PMID: 31526693.
143. Westfall JC, Cheng TW, **Farber A**, Jones DW, Eslami MH, Kalish JA, Rybin D, Siracuse JJ. *Hypoalbuminemia predicts increased readmission and emergency department visits after lower extremity bypass.* Vasc Endovasc Surg (in press)
144. Levin SR, **Farber A**, Cheng TW, Arinze N, Jones DW, Rybin D, Siracuse JJ. *Patients undergoing interventions for claudication experience low perioperative morbidity but are at risk for worsening functional status and limb loss* J Vasc Surg. (in press).
145. Villarreal Rodriguez MF, Siracuse JS, Menard M, Assmann SA, Siami FS, Rosenfield K, Strong M, **Farber A**. *Enrollment Obstacles in a Randomized Controlled Trial: A Performance Survey of Enrollment in BEST-CLI sites.* Ann Vasc Surg 2019 Sep 03. PMID: 31491479.

146. Levin SR, De Geus S, Noel N, Paasche-Orlow M, **Farber A**, Siracuse JJ. *Vascular repairs in gynecologic operations are uncommon but predict major morbidity and mortality.* J Vasc Surg. 2020 Feb 05. PMID: 32035777.
147. Levin SR, **Farber A**, Goodney PP, Schermerhorn ML, Patel VI, Arinze N, Cheng TW, Jones DW, Rybin D, Siracuse JJ. *Shunt intention during carotid endarterectomy in the early symptomatic period and perioperative stroke risk.* J Vasc Surg. 2020 Feb 05. PMID: 32035768.
148. Siracuse JJ, **Farber A**, Cheng TW, Jones DW, Kalesan B. *Lower extremity vascular injuries caused by firearms have a higher risk of amputation and death compared with non-firearm penetrating trauma.* J Vasc Surg. 2020 Feb 27. PMID: 32115320.
149. Marston WA, Kirsner RS, Tallis A, Hanft JR, Walters J, **Farber A**. *Economic benefit of a novel dual-mode ambulatory compression device for treatment of chronic venous leg ulcers in a randomized clinical trial.* J Vasc Surg Venous Lymphat Disord (in press)
150. Dicken QG, Cheng TW **Farber A**, Levin SR, Jones DW, Malas MB, Tan TW, Rybin D, Siracuse JJ. *Patients with human immunodeficiency virus do not have inferior outcomes after dialysis access creation.* J Vasc Surg. 2020 Apr 07. PMID: 32276018
151. Dakour-Aridi H, Ou MT, Locham S, Mathlouthi A, **Farber A**, Malas MB. *Anemia as an independent predictor of adverse outcomes after carotid revascularization.* J Vasc Surg. 2020 Apr 02. PMID: 32249047
152. Arinze N, Ryan T, Pillai R, Vilvendhan R, **Farber A**, Jones DW, Rybin D, Levin SR, Cheng TW, Siracuse JJ. *Perioperative and long-term outcomes after percutaneous thrombectomy of arteriovenous dialysis access grafts.* Vasc Surg. 2020 Apr 11. PMID: 32289439.
153. Raulli SJ, Sather K, Dicken QG, **Farber A**, Kalish JA, Eslami MH, Zhang Y, Cheng TW, Levin SR, Siracuse JJ. *Higher body mass index is associated with reinterventions and lower maturation rates after upper extremity arteriovenous access creation.* J Vasc Surg (in press)
154. Cheng TW, Pointer KE, Gopal M, **Farber A**, Jones D, Eberhardt E, Kalish JA, Eslami MH, Rybin D, Siracuse JJ. *Natural history of non-operative management in asymptomatic patients with 70-80% internal carotid artery stenosis by duplex criteria.* Eur J Vasc Endovasc Surg (in press)
155. Mendez L, Zhao G, Elsawawi M, **Farber A**, Bowden A, Sharpe C, Schulze R, Siracuse JJ. *A Cost analysis of pathology evaluation of carotid plaque after endarterectomy.* Ann Vasc Surg (in press)

156. Levin SR, **Farber A**, Arinze N, Talutis SD, Chang TW, Malas MB, Tan TW, Rybin D, Siracuse JJ. *Intravenous drug use history is not associated with poorer outcomes after arteriovenous access creation*. J Vasc Surg (in press)
157. Cheng TW, Boelitz K, Rybin D, Menard MT, Kalish JA, Siracuse JJ, **Farber A**, Jones DW. *Nationwide patterns in publicly available industry payments to academic vascular surgeons*. J Vasc Surg (in press).
158. Paredes LG, Arinze NV, **Farber A**, Garofalo D, Cheng, Levin SR, Vilvendhan R, Siracuse JJ. *Peri-procedural outcomes in patients on chronic anticoagulation undergoing fistulograms*. Ann Vasc Surg (in press)
159. Levin SR, **Farber A**, Osborne NH, Beck AW, McFarland GE, Rybin D, Cheng TW, Siracuse JJ. *Tibial Bypass in Patients with Intermittent Claudication Is Associated with Poor Outcomes*. J Vasc Surg (in press).

### ***Invited Reviews***

1. **Farber A** and Major K. *Cryopreserved saphenous vein allograft in infrainguinal arterial reconstruction*. J Cardiovasc Surg 45(3):213-6, 2004.
2. **Farber A** and Woo K. *Transposed arteriovenous fistulae: Do the results justify the effort?* Semin Vasc Surg 20:148-157, 2007
3. **Farber A**. *Transitioning from fellowship to practice: What every vascular surgery resident or fellow needs to know*. Endovascular Fellow Today. October 2009
4. Tan TW and **Farber A**. *Brachiobasilic autogenous access*. Semin Vasc Surg June 2011; 24(20): 63-71.
5. Carruthers TN and **Farber A**. *Current state of affairs in the treatment of infrainguinal critical limb ischemia*. Angiology and Vascular Surgery. 2013; 2(19):129-137.
6. **Farber A**, Rosenfield K, Menard M. *The BEST-CLI Trial: A multidisciplinary effort to assess which therapy is best for patients with critical limb ischemia*. Tech Vasc Interv Radiol. 2014 Sep; 17(3):221-4.
7. Menard M and **Farber A**. *BEST-CLI Trial: multidisciplinary effort to assess whether surgical or endovascular therapy is better for patients with critical limb ischemia*. Semin Vasc Surg. 2014 Mar; 27(1):82-4.
8. Conte MS and **Farber A**. *Revascularization for chronic limb threatening ischaemia*. Br J Surg. 2015 Aug; 102(9):1007-9.
9. Stoner MC, Calligaro KD, Chaer, RA, Dietzek AM, **Farber A**, Guzman RJ, Hamdan AD, Landry GJ, Yamaguchi DJ. *Reporting standards of the Society for Vascular Surgery for*

*endovascular treatment of chronic lower extremity peripheral artery disease: Executive Summary.* J Vasc Surg 2016;64(1):227-228.

10. Stoner MC, Calligaro KD, Chaer, RA, Dietzek AM, **Farber A**, Guzman RJ, Hamdan AD, Landry GJ, Yamaguchi DJ. *Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic lower extremity peripheral artery disease.* J Vasc Surg 2016;64(1):e1-e21.
11. **Farber A** and Eberhardt RT. *The current state of critical limb ischemia.* JAMA Surg 2016;151(11):1070-1077.
12. Siracuse JJ, **Farber A**. *Is open vascular surgery or endovascular surgery the better option for lower extremity arterial occlusive disease?* Adv Surg. 2017 Sep; 51(1):207-217. PMID: 28797341.
13. **Farber A**. *Chronic Limb-Threatening Ischemia.* N Engl J Med. 2018 07 12; 379(2):171-180. PMID: 29996085.
14. **Farber A**, Rosenfield K, Siami FS, Strong M, Menard M. *The BEST-CLI trial is nearing the finish line and is worth the wait.* J Vasc Surg 2019;69:470-481. PMID: 30683195.
15. Jones DW, **Farber A**. *Review of the Global Vascular Guidelines on the Management of Chronic Limb Threatening Ischemia.* JAMA Surgery (in press)
16. Motaganahalli R, Menard M, Koopmann M, **Farber A**. *BEST Endovascular versus Best Surgical Therapy in patients with Critical Limb Ischemia (BEST-CLI).* Vascular & Endovascular Review (in press)

#### ***Case Reports (peer-reviewed)***

1. **Farber A**, Grigoryants, V, Palac, DM, Chapman, T, Cronenwett, JL, Powell, R.J. *Primary aortoduodenal fistula in a patient with a history of intravesical therapy for bladder cancer with bacillus Calmette-Guerin: Review of primary aortoduodenal fistula without abdominal aortic aneurysm.* J. Vasc Surg 33(4):868-73, 2001.
2. Woodward EB, **Farber A**, Wagner WH, Cossman DV, Cohen JL, Silverman J, Levin PM, Frisch DM. *Delayed retroperitoneal arterial hemorrhage after inferior vena cava (IVC) filter insertion: Case report and literature review of caval perforations by IVC filters.* Ann Vasc Surg 16:163-7, 2002.
3. Arteaga VA, **Farber A**, Wagner WH, Lauterbach SR, Cossman DV, Cohen JL, Levin, PM. *Septic embolization to the carotid bifurcation presenting as carotidynia.* Ann Vasc Surg 17; 152-155, 2003

4. **Farber A**, Lauterbach SR, Wagner WH, Cossman DV, Long B, Cohen JL, Levin PM. *Spontaneous infrarenal abdominal aortic dissection presenting as claudication: Case report and review of the literature.* Ann Vasc Surg 18: 4-10, 2004.
5. Lauterbach SR, **Farber A**, Shortell CK. *Acute aortic dissection presenting as rupture of the femoral artery.* Ann Vasc Surg 18:11-13, 2004.
6. Vladimir FG, **Farber A**, Oropallo A, Woodson J, Gibbons G. *Unusual presentations of ruptured abdominal aortic aneurysm: Case report and review of the literature.* Romanian J Angiol Vasc Surg 8 (1-2): 41-44, 2007.
7. Magge D, **Farber A**, Vladimir F, Woodson J, Collins K, Shaw, Gibbons G. *Diagnosis and management of traumatic pseudoaneurysm of the carotid artery: Case report and review of the literature.* Vascular 16: 350-55, 2008
8. Joglar F, Kabutey N, Maree A, **Farber A**. *The role of stent-grafts in the management of traumatic tibial artery pseudoaneurysms: Case report and review of the literature.* Vasc Endovasc Surg 44(5):407-409, 2010.
9. Barman P and **Farber A**. *Traumatic pseudoaneurysm of the visceral aortic segment managed using both open surgery and endovascular therapy: A case report and review of the literature.* Ann Vasc Surg 2011 Aug; 25(6):840.e13-7
10. Tan TW, Bohannon WT, Mattos MA, Hodgson KJ, **Farber A**. *Percutaneous mechanical thrombectomy and pharmacologic thrombolysis for renal artery embolism: Case report and review of endovascular treatment.* Int J Angiology 20(2):111-117, 2011
11. Tan TW, **Farber A**. *Percutaneous endovascular repair of abdominal aortic aneurysm with coexisting horseshoe kidney: Technical aspects and review of the literature.* Int J Angiology 2011; 20(4):247-250.
12. Tobler WT, Tan TW, **Farber A**. *Endovascular repair of a blunt abdominal aortic injury.* Int J Angiology 2012; 21(2):117-120.
13. Rastogi N, Kabutey, N, Kim D, **Farber A**. *Symptomatic fibromuscular dysplasia of the external iliac artery: Case report and review of the literature.* Ann Vasc Surg 2012; 26:574-578.
14. Chong CC, Tan TW, **Farber A**. *Image of the Month: Carotid mycotic aneurysm.* JAMA Surg. 2013 Sep; 148 (9):893.
15. Tan TW, Kenney R, **Farber A**. *Left arterial thoracic outlet syndrome.* Texas Heart Institute J 2014;41:105-106.
16. Carruthers TN and **Farber A**. *Fifty-nine-year-old man with abrupt onset claudication,* J Vasc Surg 2014 Dec; 60(6):1664.

17. Kerkar A, **Farber A**, Kalish JA, Siracuse JJ. *Recurrent lower extremity compartment syndrome after four-compartment fasciotomy secondary to acute limb ischemia*. Ann Vasc Surg 2016 Jan; 30:306.e5-7
18. Sridhar P, Hardouin S, Cheng T, **Farber A**, Suzuki K, Jones DW. *Endovascular Exclusion and Open Resection of Aberrant Pulmonary Artery Aneurysm Associated with Intralobar Pulmonary Sequestration*. J Vasc Surg 2019;70(4):1328-9. PMID: 3154317.
19. Levin SR, McAneny D, Soto JA, Durfee JK, Siracuse JJ, **Farber A**. *Open resection of inferior vena caval leiomyomatosis invading an intravascular filter*. J Vasc Surg Venous Lymphat Disord 2020 Mar; 8(2):285-286. PMID: 32067730.
20. Levin SR, **Farber A**, Siracuse JJ. *Preservation of heparin-bonded prosthetic graft for hemodialysis in the setting of early heparin-induced thrombocytopenia*. Ann Vasc Surg 2020; 65: 282.e1–282.e3

### ***Commentary and Letters***

1. Ascher E, **Farber A**, Kalra M, Timaran CH, Zhou W. *Introduction to beyond borders: Proceedings from the 2100 WFVS meeting and selected international papers*. J Vasc Surg. 2013 Feb; 57(2 Suppl):1S-2S.
2. **Farber A** and Tan TW. Response to Letter to the Editor regarding *Intraoperative use of dextran is associated with cardiac complications after carotid endarterectomy*. J Vasc Surg 2013;58(4):1167.
3. **Farber A**. *Utility of the angiosome construct*. J Vasc Surg 2017 Feb; 65(2):430. PMID: 28126174.
4. **Farber A**. *Endovascular treatment for claudication still awaits long-term results*. J Vasc Surg. 2017 Jul; 66(1):1. PMID: 28647032.
5. **Farber A**. *Multi release paclitaxel-coated angioplasty balloon is a step forward but focus needs to be on paclitaxel safety*. J Vasc Surg (in press).
6. **Farber A**. *Clinical correlation of vein graft adaptation*. J Vasc Surg (in press).

### ***Book Chapters***

1. **Farber A** and J Cronenwett. “Symptomatic Carotid Stenosis” in Cronenwett and Rutherford. *Decision Making in Vascular Surgery*. WB Saunders Company: 28-33, 2001.
2. **Farber A** and J Cronenwett “Asymptomatic Carotid Stenosis” in Cronenwett and Rutherford. *Decision Making in Vascular Surgery*. WB Saunders Company: 34-37, 2001.



3. **Farber A.** “*Biological Grafts*” in Rutherford Vascular Surgery, 7<sup>th</sup> edition. Elsevier:1350-1363, 2010.
4. Kalish JA and **Farber A.** “*Outcomes and Advances in Bypass Surgery*” in Sen C (ed): Wound Healing Society Yearbook: Advanced in Wound Care, Volume 2. New Rochelle: Mary Ann Liebert, Inc.; 2011. p. 279-284.
5. **Farber A** and Tan TW. “*Endovascular Treatment of Popliteal Artery Aneurysms: The Role of Stent-grafts and Thrombolysis*” in Haimovici’s Vascular Surgery Wiley-Blackwell:811-820, 2011
6. Tan TW and **Farber A.** “*Management of Peripheral Arterial Emboli*” in Current Surgical Therapy, 11<sup>th</sup> ed. Elsevier, 2014
7. Kalish JA and **Farber A.** “*Biological Grafts*” in Rutherford’s Vascular Surgery, 8<sup>th</sup> edition. Elsevier, 2014 p.1419-1430.
8. **Farber A.** “*Dealing with the Non-Maturing Arteriovenous Fistula*” in Northwestern Textbook of Vascular Surgery, PMPH USA, 2015
9. Siracuse JJ and **Farber A.** “*In Patients with Critical Limb Ischemia Does Bypass Improve Limb Salvage and Quality of Life When Compared to Endovascular Revascularization?*” in Difficult Decisions in Surgery: An Evidence-Based Approach, Springer, 2017, <http://link.springer.com/book/10.1007/978-3-319-33293-2>
10. Siracuse JJ and **Farber A.** “*Complications Following Extra-anatomic Bypass for Aorto-iliac Occlusive Disease*” in Prevention and Management of Vascular and Endovascular Complications. People's Medical Publishing House, 2015
11. Siracuse JJ and **Farber A.** “*Current Perspectives in Peripheral Arterial Disease in North America*” in Vascular Surgery: A Global Perspective, Springer, 2015
12. **Farber A** and Pike S. *Forearm versus Upper Arm Arteriovenous Graft for Dialysis Access: Which is Preferred?* In Northwestern Textbook of Vascular Surgery, PMPH USA, 2017.
13. Kalish JA and **Farber A.** “*Biological Grafts*” in Rutherford’s Vascular Surgery, 9<sup>th</sup> edition. Elsevier, 2018, p.832-844.
14. Siracuse JJ and **Farber A.** “*Vascular Grafts: Characteristics and Rational Selection*”. In Moore: Vascular and Endovascular Surgery, 9<sup>th</sup> edition, Elsevier (in press)
15. Tan TW and **Farber A.** *Operative Management of Portal Vein/Superior Mesenteric Vein Trauma: Can We Just Ligate?* In Hepato-Pancreato-Biliary and Transplant Surgery: Practical Management Of Dilemmas. Beaux Books (in press)

16. Tan TW and **Farber A.** “*Peripheral Arterial Disease*” in Vascular Imaging and Endovascular Interventions, 2<sup>nd</sup> edition, Jaypee Brothers Medical Publishers, 2019, p1357-74.
17. Carruthers TN and **Farber A.** “*Abdominal and Pelvic Trauma*” in Vascular Imaging and Endovascular Interventions, 2<sup>nd</sup> edition, Jaypee Brothers Medical Publishers, 2019, p1097-1132.
18. **Farber A** and Pike S. ”*Noise and Distraction during Procedures*”. In Essential Principles in Patient Safety: An Illustrated Manual for the Health Care Team. Boston Medical Center. (in press)
19. Jones DW and **Farber A.** “*Vascular Trauma*” in Vascular Medicine: A Companion to Braunwald’s Heart Disease, 3<sup>rd</sup> edition, Elsevier (in press)
20. **Farber A** and Hardoiun S. **Farber A** and Pike S. “*Femoral Vein Transposition Arteriovenous Fistula: How Does it Compare with Other Lower Extremity Hemodialysis Access?*” In Northwestern Textbook of Vascular Surgery, PMPH USA, (in press).
21. Jones DW and **Farber A.** Chronic Mesenteric Ischemia. Current Surgical Therapy, 13<sup>th</sup> ed. (in press)

#### **INVITED PODIUM PRESENTATIONS (*Selected Regional, National and International*)**

1. “The Achievements of the Soviet/American Medical Student Exchange Project (an educational, student-organized exchange between medical students from Harvard Medical School and Second Moscow Pirogov Medical School)”. IXth Congress of the International Physicians for the Prevention of Nuclear War, **Hiroshima, Japan**, 10/89.
2. “Comparison of angiography, intravascular ultrasound, axial CT, and 3-D CT scanning in a three-dimensional aneurysm model”. XIth International Congress for Endovascular Interventions, **Scottsdale, AZ**, 2/98  
14th Annual Vascular Fellows Abstract Presentation, **New York, NY**, 4/98
3. “A specific apoptosis inhibitor improves intestinal viability following ischemia-reperfusion”. Frederick A. Collier Surgical Society, **Williamsburg, VA**, 10/9
4. “A caspase inhibitor decreases oxidized low density lipoprotein-induced apoptosis in bovine endothelial cells”. Association for Academic Surgery, **Seattle WA**, 11/98
5. “Isolated dissection of the abdominal aorta: Clinical presentation and therapeutic options”. Western Vascular Society, **Santa Fe, NM**, 9/01

6. "What does a Vascular Surgeon do? Assessment of public knowledge about Vascular Surgery" International Society for Vascular Surgery (Veith Symposium), **New York, NY** 11/04.
7. "Blood management in trauma" 2<sup>nd</sup> Baltic Congress on Transfusion Practice and Transfusion Alternatives, **Riga, Latvia**, 6/05
8. "What does a Vascular Surgeon do? Assessment of public knowledge about Vascular Surgery" New England Vascular Society, **Stowe, VT**, 10/05
9. "Current status of cryopreserved saphenous vein as arterial replacement grafts: Results are better than you think" VEITH Symposium, **New York, NY** 11/05
10. "Management of Critical Limb Ischemia: Is there still a role for surgical revascularization?" Endovascology 2005, **Shanghai, China**, 12/05
11. "New concepts in the management of lower extremity peripheral arterial disease: Surgical and endovascular options" 3<sup>rd</sup> Baltic Congress on Transfusion Practice and Transfusion Alternatives, **Riga, Latvia**, 7/06
12. "Outcomes of transposed upper arm arteriovenous fistulae – Does type of vein matter?" Veith Symposium, **New York, NY** 11/06.
13. "Management of isolated dissection of the abdominal aorta" Endovascology 2006, **Shanghai, China**, 11/06
14. "Transposed arteriovenous fistulae for dialysis access: Do they work better than prosthetic arteriovenous grafts?"  
"Current management of infrainguinal peripheral arterial occlusive disease: Role of surgical and endovascular revascularization"  
The 7<sup>th</sup> National Congress of Romanian Society of Angiology and Vascular Surgery, **Oradea, Romania**, 5/2007
15. "Complications of A-V access and their management" Updates and Advances in Vascular and Endovascular Surgery – 2007. Massachusetts General Hospital Vascular Course, **Boston, MA**, 5/2007
16. "Everything you wanted to know about critically evaluating a vascular practice but were afraid to ask" Young Vascular Surgeon Dinner Symposium. Society for Clinical Vascular Surgery, **Las Vegas, NV**, 3/2008.
17. "Complications of A-V access and their management" Updates and Advances in Vascular and Endovascular Surgery – 2008. Massachusetts General Hospital Vascular Course, **Boston, MA**, 5/2008

18. “Surgical Management of PAD: What are the current options?” The 23<sup>rd</sup> Annual Smithwick Symposium: Recent Advances in Management of Peripheral Arterial Disease, **Boston, MA**, 11/7/2008
19. “A Third Year Surgical Clerkship With Extensive Exposure To Vascular Surgery Improves Knowledge About Vascular Diseases And The Role Of Vascular Surgeons.” Association for Academic Surgery Academic Surgical Congress, **Fort Myers, FL**, 2/2009.
20. “Endovascular management of the popliteal artery: Comparison of atherectomy and angioplasty”,  
“Comparison of the efficacy of upper arm transposed arteriovenous fistulae and upper arm prosthetic grafts: Analysis of 358 matched procedures. Society for Clinical Vascular Surgery, **Ft. Lauderdale, FL**, 3/2009
21. “How to use catheter-based interventions for SFA and tibial disease.” Massachusetts General Hospital Vascular Course, **Boston, MA**, 5/2009
22. “Private vs. Academic Practice: How Different Are They And What Are The Pros And Cons?”, Society for Vascular Surgery Annual Meeting, **Denver, CO**, 6/2009
23. “The role of gender in vascular trauma: A review of the National Trauma Data Bank” 51<sup>st</sup> Annual World Congress of International College of Angiology, **Beijing, China**, 10/2009
24. “Revascularization in Patients with Diabetes and Critical Limb Ischemia: Open Surgery or Endovascular Therapy?” Russian Academy of Medical Sciences Symposium on the Endovascular Treatment of Non-Coronary Cardiovascular Diseases, **Kemerovo, Russia**, 1/2010
25. “The Evaluation of a Novel Technique to Treat Saphenous Vein Incompetence: Preclinical Animal Study to Examine Safety and Efficacy of the V-Block Device”, Society of Interventional Radiology National Meeting, **Tampa, FL**, 3/2010
26. “How to use catheter-based interventions for SFA and tibial disease.” Massachusetts General Hospital Vascular Course, **Boston, MA**, 5/2010
27. “How to succeed after your fellowship” Society for Vascular Surgery Annual Meeting, **Boston, MA**, 6/2010.
28. “The Effect of Parental Occurrence of Intermittent Claudication on Risk of Intermittent Claudication in Adult Offspring: A Prospective Study of Parents and Offspring in the Framingham Heart Study.” 11<sup>th</sup> Annual Congress of Asian Society for Vascular Surgery, **Kyoto, Japan**, 6/2010.
29. “Diagnosis and Imaging of Acute Limb ischemia”, “Lower Extremity Aneurysms”. Cardiovascular Fellows’ Bootcamp, **Houston, TX**, 8/2010

30. “Early Fasciotomy in Patients with Extremity Vascular Injury is Associated with Decreased Risk of Adverse Limb Outcomes: A Review of the National Trauma Data Bank.” 37<sup>th</sup> Annual Meeting of the New England Society for Vascular Surgery, **Rockport, ME**, 9/2010.
31. “Strategies for Management of Critical Limb Ischemia in 2010”,  
 “How Does an American Vascular Surgeon Treat Carotid Artery Occlusive Disease in 2010”,  
 “Infrainguinal Bypass or Endovascular Intervention?– How Vascular Surgeons Choose Treatment Strategy for Patients with Critical Limb Ischemia”. 22<sup>nd</sup> International Conference of the Russian Society of Vascular Surgery and Angiology. **Moscow, Russia**, 11/2010
32. “The Role of Hybrid Vascular Procedures in the Treatment of Peripheral Arterial Disease” 4<sup>th</sup> Russian Congress of Interventional Cardioangiography, **Moscow, Russia**, 3/2011
33. “How to Use Catheter-based Interventions for SFA and Tibial Disease.” Massachusetts General Hospital Vascular Course, **Boston, MA**, 5/2011
34. “The Use of Non-invasive Vascular Studies in AV Access: Preoperative Assessment and Surveillance”, Postgraduate Course, New England Society for Vascular Surgery Annual Meeting, **Providence, RI**, 9/2011
35. “How to Manage Lower Extremity Peripheral Arterial Disease”-session co-moderator  
 “The Role of Imaging in the Diagnosis and Management of PAD” – speaker  
 American College of Surgeons 97<sup>th</sup> Annual Clinical Congress, **San Francisco, CA**, 10/2011
36. “The Role of Hybrid Procedures in the Armamentarium of a Vascular Surgeon”, XVI<sup>th</sup> Annual St. Petersburg Angiology Symposium, **St. Petersburg, Russia**, 12/2011
37. “Angiogenesis/Ischemia/Reperfusion”- session co-moderator  
 7<sup>th</sup> Annual Academic Surgical Congress, **Las Vegas, NV**, 2/2012.
38. “Surgical Bypass or Endovascular Therapy?: How Vascular Surgeons Decide for Patients with Infrainguinal Arterial Disease and Critical Limb Ischemia”40<sup>th</sup> Symposium of the Society for Clinical Vascular Surgery, **Las Vegas, NV**, 3/2012.
39. “The Role of Hybrid Procedures in Critical Limb Ischemia”, 2<sup>nd</sup> Annual Symposium on the Endovascular Management of Critical Limb Ischemia (KINK ’12), **Moscow, Russia**, 4/2012.
40. “Intraoperative Use of Dextran is Associated with Cardiac Complications after Carotid Endarterectomy”, Society for Vascular Surgery Vascular Annual Meeting, **Washington D.C.**, 6/2012.
41. “Critical Limb Ischemia is Best Treated Using Infrainguinal Bypass”. 23<sup>rd</sup> International Conference on Current Issues in Vascular Surgery. **St. Petersburg, Russia**, 6/2012.

42. "Management of the Non-Maturing Arteriovenous Fistula". 16<sup>th</sup> Annual Max R. Gaspar Symposium (Controversies and Challenges in Hemodialysis Access), Keck School of Medicine of the University of Southern California, **Los Angeles, CA**, 9/27/2012.
43. "Hybrid Procedures to Treat PAD",  
"The Current State of Carotid Surgery",  
"Choice of Therapy to Treat Critical limb Ischemia",  
"Current Methods to Assess and Treat Compartment Syndrome". Secrets of Vascular Surgery 2012: New Methods of Treatment of Vascular Disease. Symposium of the Ukrainian Vascular Society, **Kiev, Ukraine**. 10/18-19/2012.
44. "Open vs. Endovascular Repair of Popliteal Artery Aneurysm (OVERPAR) Trial". Vascular Rounds, University of Massachusetts Vascular Surgery Division, **Worcester, MA**, 11/21/2012.
45. "Critical Limb Ischemia and the BEST Trial: Lessons Learned in Clinical Trial Organization". Surgical Grand Rounds, VA Boston Healthcare System, **Boston, MA** 11/30/2012.
46. "How to Use Catheter-based Interventions for SFA and Tibial Disease." Massachusetts General Hospital Vascular Course, **Boston, MA**, 4/27/2013
47. "Failure to Mature – The Role of Surveillance and Intervention", Current Challenges in Hemodialysis Access Postgraduate Course,.  
"Patency of Forearm and Upper Arm Hemodialysis Arteriovenous Grafts: Does Configuration or Location Matter?, Society for Vascular Surgery Plenary Session, Vascular Annual Meeting, **San Francisco, CA**, 5/31/2013.
48. "Management of Acute Limb Ischemia", "Vascular Surgery in the United States--Trends and Realities". New Approaches to the Management of Patients with Peripheral Vascular Disease, 28th International Congress, **Novosibirsk, Russia**, 6/28-29/2013
49. "Management of the Non-maturing Fistula", American College of Surgeons Annual Meeting, **Washington, D.C.**, 10/9/2013
50. "The BEST-CLI Trial: What It Will Tell Us About The Treatment Of Lower Extremity CLI And Why It Is Unique" Grasberger Symposium, Boston Medical Center, **Boston, MA**, 4/7/2014.
51. "Can Drug Eluting Stents or Covered Stent-grafts Improve Results of Lower Extremity Endovascular Therapy?",  
"Optimal Strategies for End Stage Renal Disease Hemodialysis Access" Massachusetts General Hospital Vascular Course, **Boston, MA**, 4/24-25/2014.

52. “Critical Limb Ischemia – Surgical versus Endovascular Revascularization: How to Choose”, The 43<sup>rd</sup> Annual Samuel D. Plotkin Cardiovascular Symposium (Baystate Medical Center), **Holyoke, MA**, 4/29/2014.
53. “Critical Limb Ischemia - Surgical versus Endovascular Revascularization: How to Choose?; “Endovascular Treatment of Femoro-Popliteal In-stent Restenosis”  
”When to Treat an Asymptomatic Carotid Stenosis?” XIII Encontro Mineiro De Angiologia E Cirurgia Vascular (Brazilian Society for Vascular Surgery Symposium), **Belo Horizonte, Brazil**, 5/15-17/2014.
54. “BEST-CLI Trial: Design and Measures”, 6/4/2014; “A Comparison of Superficial Femoral Artery Treatment Strategies for Critical limb Ischemia in the Vascular Quality Initiative”, 6/6/2014. Society for Vascular Surgery Vascular Annual Meeting, **Boston, MA**, 6/4-7, 2014.
55. “BEST-CLI Trial: What it Will Teach us About Critical Limb Ischemia”  
“The Role of Transcutaneous Oximetry in Peripheral Arterial Disease” New Directions and Outcomes of Open and Endovascular Treatment Strategies in the Management of Vascular Patients -29<sup>th</sup> International Congress, **Ryazan, Russia**, 6/28/2014.
56. “Critical Limb Ischemia is Best Treated with Endovascular Therapy”; “How to Get a Clinical Trial Started” International Society for Vascular Surgery Congress, **Guangzhou, China**, 7/11/2014.
57. “Surgeon’s Intraoperative Assessments During Autogenous Arteriovenous Fistula Creation Strongly Correlate with Early Fistula Thrombosis”. Joint Annual Meeting of the New England Society for Vascular Surgery and Eastern Society for Vascular Surgery, **Boston, MA**, 9/14/2014
58. “Open vs. Endovascular: Which is BEST?” 18<sup>th</sup> Annual Max R. Gaspar Symposium (Peripheral Arterial Disease in 2014), Keck School of Medicine of the University of Southern California, **Los Angeles, CA**, 9/18/2014.
59. “Best Endovascular versus Surgical Therapy for Critical Limb Ischemia (BEST-CLI) Trial” European Society for Vascular Surgery XXVIII Annual Meeting, **Stockholm, Sweden**, 9/24/2014.
60. “Critical Limb Ischemia Risk Stratification: Defining Expectations and Determining Salvageability” Vascular Interventional Advances (VIVA), **Las Vegas, NV**, 11/3/2014.
61. “Dealing with the Non-maturing Arteriovenous Fistula”, 39<sup>th</sup> Annual Northwestern Vascular Symposium, **Chicago, IL**, 12/11/2014.
62. “Best Endovascular versus Surgical Therapy for Critical Limb Ischemia (BEST-CLI) Trial” Society for Clinical Vascular Surgery, **Miami, FL**, 4/2/2015.

63. “Society for Vascular Surgery Guidelines and Optimizing Strategies of Hemodialysis Access” Massachusetts General Hospital Vascular Course, **Boston, MA**, 5/1/2015.
64. “Update on the BEST-CLI Trial: Are we Going to Have Answers When We Are Done?”, Pacific Northwest Endovascular Conference, **Seattle, WA**, 5/21/2015
65. “Update on the BEST-CLI Trial”, Eastern Vascular Society, **Baltimore, MD**, 9/25/2015.
66. “Does Duplex Play a Role in Surveillance of Dialysis Access and How Does it Guide Intervention?”, Postgraduate Course, New England Society for Vascular Surgery, **Newport, RI**, 10/2/2015.
67. “Treatment of Acute Limb Ischemia”,  
“Update on the BEST-CLI Trial”, 31<sup>st</sup> International Conference: Special Topics in Vascular Surgery, **Moscow, Russia**, 11/25/2015.
68. “The Current State of Critical Limb Ischemia”, Surgery Grand Rounds, Mt. Sinai Medical Center, **New York, NY**, 1/27/2016.
69. “Screening Failures in the BEST-CLI Trial Provide Perspectives for Trial Implementation”, 44<sup>th</sup> Annual Symposium of the Society for Clinical Vascular Surgery, **Las Vegas, NV**, 3/13/2016.
70. “How Do I Decide Between Endo and Open (for Patients with Critical Limb Ischemia)” Masters’ Approach to Critical Limb Ischemia (MAC) Symposium, **Cleveland, OH**, 4/17/2016.
71. “BEST-CLI Trial Update”, Charing Cross International Symposium, **London, England**, 4/28/2016.
72. “The BEST Approach to CLI – Open vs. Endo?” National Capital Vascular Symposium: Peripheral Arterial Disease, **Ottawa, Canada**, 5/7/2016.
73. “How Do I Decide Between Endo and Open for Patients with Critical Limb Ischemia”, Pacific Northwest Endovascular Conference Simulation Summit for Vascular Trainees, **Seattle, WA**, 5/24/2016.
74. “The Best Approach to CLI in 2016: Open Vascular Surgery or Endovascular Therapy?”, IX<sup>th</sup> Scientific Conference dedicated to the 100<sup>th</sup> Anniversary of Academician Y.E. Mishalkin, **Novosibirsk, Russia**, 6/17/2016.
75. “Infrainguinal Lower Extremity Bypass to Tibial and Pedal Targets,”-- Postgraduate Course, “BEST-CLI Update”, New England Society for Vascular Surgery, **Stowe, VT**, 9/24/2016.



76. “Critical Limb Ischemia and the BEST Trial: Lessons Learned” (*Presidential Guest Lecture*), “BEST-CLI Trial: What are we Expecting to See and How is the Trial Faring thus Far”, Western Society for Vascular Surgery, **Colorado Springs, CO**, 9/26/2016
77. “In Popliteal Artery Aneurysm, Great Saphenous Vein Interposition or Bypass Graft Provide the Best Long Term Outcome”, European Society for Vascular Surgery/Society for Vascular Surgery Debate, European Society for Vascular Surgery 30<sup>th</sup> Annual Meeting, **Copenhagen, Denmark**, 9/30/2016.
78. “The BEST-CLI Trial: A Multidisciplinary Effort at Work!”, Vascular and Endovascular Surgery Society (VESS) Winter Annual Meeting, **Steamboat Springs, CO**, 2/3/2017.
79. “Evaluation of Patient with Acute Limb Ischemia”,  
“Current Challenges in the Diagnosis and Treatment of Critical Limb Ischemia”, 29<sup>th</sup> International Symposium on Endovascular Therapy (ISET), **Hollywood, FL**, 2/5-6/2017.
80. “Update on the BEST-CLI Trial:”, “Debate: Endovascular Therapy is the Best Initial Treatment for Anatomically Suitable Patients” Massachusetts General Hospital Vascular Course, **Boston, MA**, 4/27-30/2017.
81. “BEST-CLI Trial Update”, “Trial Execution - Tips from the BEST-CLI Trial Investigators”, Society for Vascular Surgery Annual Meeting, **San Diego, CA**, 6/1-3/2017.
82. “Mixed Arterial and Venous Disease – How to Approach”, Innovation in Vascular Disease – Why, How and Where?”, Cardiovascular Innovations 2017, **Denver, CO**, 8/3-5/2017.
83. “BEST-CLI Trial: Why We Need to Continue to Enroll Patients and What We Have Learned So Far”, Canadian Society for Vascular Surgery 39<sup>th</sup> Annual Meeting, **Banff, Alberta, Canada**, 9/15/2017.
84. “Status of the BEST-CLI Trial – A RCT of CLI Treatments; Laudable but Difficult: It will provide Useful Information”,  
“Hospital Readmissions after Outpatient Access Creation”  
“Femoral Vein Transposition is a Durable Hemodialysis Access Creation”, VEITH Symposium, **New York, NY**, 11/14-11/18/2017.
85. “Vascular Surgery – Where should it be Performed? Perspectives from an Academic Surgeon”, 64<sup>th</sup> Annual Meeting of the Massachusetts Chapter of the American College of Surgeons, **Boston, MA**, 12/2/2017.
86. “Forearm versus Upper Arm Arteriovenous Graft for Dialysis Access: Which is Preferred?”, 42<sup>nd</sup> Annual Northwestern Vascular Symposium, **Chicago, IL**, 12/7/2017.
87. “Encouraging Patients to Enroll is a Significant Obstacle in a Randomized Controlled Trial Irrespective of Site Performance”, Vascular and Endovascular Surgery Society 42<sup>nd</sup> Annual Meeting, **Vail, CO**, 2/2/2018

88. “Debate: Endovascular Therapy is the Best Initial Treatment for Anatomically Suitable Patients”,  
“The Patient with Progressive Renal Failure: Who should get AVF/AVG or Peritoneal Catheter and When?” Massachusetts General Hospital Vascular Course, **Boston, MA**, 4/26-27/2018.
89. “Carotid Disease: A Surgeon’s Attempt to Answer Basic Clinical Questions through Outcomes Research” Michigan Vascular Study Group/BMC2 Meeting, **Traverse City, MI**, 5/17/2018.
90. “The State of Management of Critical Limb Ischemia: Is Consensus in Sight?”, Michigan Chapter of the American College of Surgeons, **Traverse City, MI**, 5/18/2018.
91. “Best-CLI Trial, Importance of Hemodynamics and the Role of SVS Wifi”, BASIL Trial Investigators’ Meeting, **Birmingham, England**, 6/6/2018.
92. “Update on the BEST-CLI Trial”, “Femoral Vein Transposition for Dialysis Access: How I Do It!” Pacific Northwest Endovascular Conference, **Seattle, WA**, 6/15/2018
93. “Durability and Long-Term Data Support Open Bypass for Diabetic Tibial Disease: Perspective from a BEST-CLI PI”  
“The Femoral Vein Transposition AVF is a Durable Hemodialysis Access in Patients who have Exhausted Upper Extremity Options”  
“Open Resection of Caval Leiomyoma and Associated Inferior Vena Cava Filter” Society for Vascular Surgery Annual Meeting, **Boston, MA**, 6/20-22/2018.
94. “The Threshold for Distal Revascularization”, European Society for Vascular Surgery Annual Meeting, **Valencia, Spain**, 9/25-28/2018.
95. “Femoral Vein and Other Atypical Dialysis Access Constructions”  
“The BEST-CLI Trial Update”  
“Younger Patients Have Worse Outcomes Following Peripheral Vascular Interventions for Suprainguinal PAD”, New England Society for Vascular Surgery, **Cape Neddick, ME**, 10/12-14/2018.
96. “Current and New Data on Morbidity and Mortality Risks after Lower Extremity Embolectomy/Thrombectomy for ALI -- Open and Endo: Is it Less than in the Past and Why? VEITH Symposium, **New York, NY**, 11/13-17/2018.
97. “Femoral Vein Transposition for Dialysis Access”, 43<sup>rd</sup> Northwestern Vascular Symposium, **Chicago, IL**, 12/6-8/2018.
98. “Clinical Practice Patterns and Bias in Randomized Trials: A Survey of Investigators in the BEST-CLI Trial”, Vascular and Endovascular Surgery Society, **Snowbird, UT**, 1/31-2/3/2019.

99. “Designing Trials Across Multiple Disciplines”, Academic Surgical Congress, **Houston, TX**, 2/5-7/2019.
100. “The Current State of Chronic Limb Threatening Ischemia’, Malcolm O. Perry Lectureship in Surgery, University of Texas Southwestern Medical Center, **Dallas, TX**, 3/26/2019.
101. “The Patient with Progressive Renal Failure: Who should get AVF/AVG or Peritoneal Catheter and When?” Massachusetts General Hospital Vascular Course, **Boston, MA**, 4/25-27/2019.
102. “The Current State of Chronic Limb Threatening Ischemia’, Berkshire Medical Center, **Pittsfield, MA**, 5/24/2019.
103. “BEST-CLI – Why this Trial is Important”, XIV Convegno Nazionale, Collegio Italiano Dei Primari Ospedalieri Di Chirurgia Vascolare, **Verona, Italy**, 6/24-25/2019.
104. “SFA/Popliteal Case I Should Have Sent to Surgery”, Cardiovascular Innovations 2019, **Denver, CO**, 7/19/2019
105. “Abdominal and Visceral Non-invasive Vascular Studies”—Postgraduate Course, “The BEST-CLI Trial Update”, New England Society for Vascular Surgery, **Providence, RI**, 9/12-14/2019.
106. “BEST-CLI Trial Update”, European Society for Vascular Surgery, **Hamburg, Germany**, 9/25/2019.
107. “The BEST-CLI Trial: What is Best for Chronic Limb Threatening Ischemia”, Surgery Biology Club II Annual Meeting, **San Francisco, CA**, 10/27/2019.